English translation

Summary of Financial Statements for the Fiscal Year Ended December 31, 2013
[Japanese GAAP] (Non-consolidated)
Company Name

SymBio Pharmaceuticals Limited

February 12, 2014
Listing: Tokyo Securities Exchange

Securities code4582

URL http://www.symbiopharma.com/

Representative

Representative Director, President andChief Executive Officer

Fuminori Yoshida

Contact person

Director, Executive Vice President andChief Financial Officer

Takashi Shimomura

TEL 03(5472) 1125

Date of dividend
payment (plan)―

Ordinary Annual General Meeting
March 27, 2014of Shareholders
Scheduled date to file Securities
ReportMarch 28, 2014

Supplementary materials for thefinancial statements

Yes

Holding of earnings performanceYes
review:

No

No (For securities analysts and institutional investors)(millions of yen – rounded down, unless otherwise stated)
1. Business Results for FY 2013 (January 1, 2013 to December 31, 2013)(Percentages indicate year-on-year changes)
Net Sales
Operating Income (loss)
Ordinary Income (loss)
Net Income (loss)
millions of yen% millions of yen% millions of yen% millions of yen%
1,532(21.6)(1,680)(1,601)(1,605)
1,955
3.9(1,700)(1,729)(1,733)-(1) Operating results

FY 2013
FY 2012Net Income (loss) per share

Diluted Net Income per
share

Yen
FY 2013
FY 2012(Reference)

Equity in earnings:(69.29)(90.60)FY 2013

Yen-

Ratio of net
Ratio of ordinary Ratio of operating
income (loss) to income (loss) to income (loss) toequity (ROE) total assets (ROA)
net sales%%%- million yen(26.3)(30.2)FY 2012(24.3)(27.1)(109.7)(87.0)- million yen(2) Financial position

FY 2013
FY 2012(Reference)

Equity:Total Assets
millions of yen

Net Assets
millions of yen

7,686
5,502

7,432
4,899

FY 2013

7,336 million yen

Equity Ratio%

Net Assets per Share
Yen

95.4
88.6

239.48254.71

FY 20124,872 million yen(3) Cash flows
Cash flows from operating Cash flows from investing Cash flows from financing Cash and cash equivalents
activities
activities
activities
at the end of the year
millions of yen
millions of yen
millions of yen
millions of yen
FY 2013
FY 2012(1,677)(1,658)(1,332)
(410)

4,056
(0)

5,294
4,240

2. Dividends
Annual Dividend per Share
1st Quarter

2nd Quarter

3rd Quarter

Fiscal Year End

Yen
0.00
0.00
0.00

Yen
-

Yen
0.00
0.00
0.00

Yen
-

FY 2012FY 2013
FY 2014 (Forecast)

Total Dividends

Payout ratio

millions of yen-%-

Full Year
Yen
0.00
0.00
0.00

Ratio ofdividends to
net assets%-

3. Earnings Forecasts for FY 2014 (January 1, 2014 to December 31, 2014)
Operating
Income (Loss)

Net Sales
millions of yen%

millions of yen

1,785

16.5

(1,654)

Full Year(Percentages indicate year-on-year changes)
Net Income (Loss)
Ordinary
Net Income (Loss)
Income (Loss)per share%-

millions of yen(1,650)%

millions of yen-(1,654)

Notes:(1) Changes in accounting policies, changes in accounting estimates and restatements after error corrections

%
-

Yen

(52.63)(a) Changes in accounting polices due to revision ofYes ・ No
accounting standards:(b) Changes in accounting polices due to otherreasons:

Yes

No(c) Changes in accounting estimates:

Yes ・ No(d) Restatements after error correction:

Yes ・ No

(2) Number of shares outstanding (common stock)(i) Number of shares outstanding at the end of
the year (including treasury stock)(ii) Number of shares of treasury stock at theend of the year(iii) Average number of shares during the year

FY 201330,634,257 shares

FY 2012

19,130,900 shares

FY 201375 shares

FY 201275 shares

FY 2013

23,167,804 shares

FY 2012

19,130,825 shares(Note) Refer to “Per share information” on Page 52 for number of shares that forms the basis for calculating net income (loss)
per share.
* The status of the annual audit
The audit of financial statements as required by the Financial Instruments and Exchange Act is proceeding as of the date of thisdisclosure document.
*Explanation regarding the appropriate uses of earnings forecasts and other matters(Notes on the forward-looking statements)
All forecasts presented in this document including earnings forecasts are based on the information currently available to the
management and the assumptions that we judge reasonable. Actual results may differ substantially from these forecasts due tovarious factors. Regarding the assumptions on which the earnings forecasts are based and its usage, please refer to “Businessresults analysis” on Page 2 of the attachment.

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

Index of the attachment
1. Business results……………………………………………………………………………………………………….………. 2(1) Business results analysis ……………………………………………………………………………………………...….. 2(2) Financial position analysis ………………………………………………………………………………………………. 3(3) Basic policies concerning profit distribution and dividends …………………………………………………………..… 4(4) Risks of business ………………………………………………………………………………………………….…...… 5
2. Situation of corporate group ………………………………………………………………………………………………... 11
3. Management policies ……………………………………………………..….………………………………………..…….. 11(1) Basic policy of company management …………………………..…………………………………………………..….. 11(2) Key performance index ………………………………………..……………………………………………….……..…. 12(3) Pipelines ……………………………………………………………………………………………………………….... 12(4) Medium to long-term strategy ………………………………………………………………………………….……...… 14(5) Issues to be solved by the Company …………………………………………………………………………………….. 14(6) Other important matters concerning the Company’s management …………………………………….………………… 15
4. Financial statements …………………………………………………………………………………………………….....… 16(1) Balance sheets …………………………………………………………………………………………………….…..… 16(2) Statements of operations ……………………………………………………………………………………………..…. 18(3) Statements of changes in net assets ……………………………………………………………………..…….……...… 19(4) Statements of cash flows …………………………………………………………………………………………..…… 21(5) Events and conditions with indicate there could be substantial doubt about going concern assumption…………….…. 23(6) Significant accounting policies …………………………………………………………………………………....….... 23(7) Notes on financial statements …………………………………………………………………………………….....….. 25(Balance sheets) …………………………………………………………………………………………………...….. 25(Statements of operations) ………………………………………………………………………………..……….….… 25(Statements of changes in net assets) …………………………………………………………………..………...…… 26(Statements of cash flows) ………………………………………………………………………………………..…... 27(Lease transactions) ……………………………………………………………………………………………..…..… 27(Financial instruments) …………………………………………………………………………………. …………… 28(Marketable and investment securities) ………………………………………………………………………….…… 33(Derivative transactions) ……………………………………………………………………………………………….. 34(Retirement benefits) ………………………………………………………………………………………….……..… 35(Stock options) ………………………………………………………………………………………………….…...… 36(Deferred tax accounting) ………………………………………………………………………………………….. … 50
(Equity in earnings) ……………………………………………………………………………………………….…… 50(Asset retirement obligations) ………………………………………………………………………………….....…… 50(Investment and rental properties) ………………………………………………………………………………..….… 50(Segment information) …………………………………………………………………………………………….…… 51(Related parties information) …………………………………………………………………………………..….…… 52(Per share information) …………………………………………………………………………………………….. … 52
(Significant subsequent events) ………………………………………………………………………………………… 53
5. Other ………………………………………………………………………………………………………………………… 53(1) Changes in Officers ……………………………………………………………………………………………………… 53(2) Other ………………………………………………………………………………………………………………..…… 53-1-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

1. Business results(1) Business results analysis(Business Results for FY 2013)
Progress in the Company’s business for FY 2013 is as follows:(i) Domestic[SyB L-0501 (the generic name: bendamustine hydrochloride, the trade name: TREAKISYM®)]
Since December 2010, the Company has marketed the anticancer drug SyB L-0501 in Japan through its business partner
Eisai Co., Ltd. (hereinafter “Eisai”), for the indications of refractory/relapsed indolent non-Hodgkin’s lymphoma andmantle cell lymphoma.
The Company has also carried out three clinical trials on TREAKISYM® for additional indications.
With respect to the Phase II clinical trial for the indications of previously untreated indolent non-Hodgkin’s lymphoma
and mantle cell lymphoma, the last enrollment was completed in October 2013, and the study data are currently being
analyzed and evaluated in preparation for submission. The application for approval in the EU has already been submitted byAstellas Pharma GmbH, and is currently being reviewed by the European Medicines Agency (hereinafter “EMA”).
The Phase II clinical trial for the indication of chronic lymphocytic leukemia was initiated in May 2013, and favorable
progress has been made with enrollment of patients. In this connection, TREAKISYM® was designated an orphan drug
(pharmaceutical for treatment of rare diseases) for the indication of chronic lymphocytic leukemia during June 2012.
Discussion about future approaches to development for refractory/relapsed aggressive non-Hodgkin’s lymphoma iscurrently being continued with the PMDA.
On the other hand, in the Phase II clinical trial on refractory/relapsed multiple myeloma, which was carried out as part ofthe expansion of indications, although a dose of 90 mg/m2 TREAKISYM® was confirmed to be safe for Japanese patientson the basis of interim results, no patients were found to respond to this treatment, and it was judged that it would be very
difficult to achieve the target response rate with TREAKISYM® monotherapy, even with inclusion of more patients in the
study, so the study was discontinued.
[SyB L-1101 (intravenous formulation) and SyB C-1101 (oral formulation), the generic name: rigosertib]
The Japanese Phase I clinical trial of the anticancer drug SyB L-1101(intravenous formulation) for the indication ofrefractory/relapsed myelodysplastic syndrome (MDS), a type of blood tumor, has been continued.
With respect to SyB C-1101(oral formulation), the Japanese Phase I clinical trial for the intended indication of previously
untreated MDS was initiated in March 2013.
[SyB D-0701]
The Phase II clinical trial of SyB D-0701, a transdermal antiemetic patch, for the indication of radiotherapy-induced
nausea and vomiting was completed during January 2013. However, the expected results with respect to efficacy were notachieved.
(ii) Overseas
SyB L-0501 sold largely as planned in South Korea, Taiwan and Singapore. In Singapore and South Korea, we sell the
product through Eisai, as we do in Japan, and the sales figures have been going up steadily.
(iii) Fund procurement
The Company made a resolution on December 27, 2012 to issue the first unsecured convertible bond with stockacquisition rights (total issue price: 1 billion yen) with Whiz Healthcare PE Series 1 Investment Limited Liability
Partnership as the allottee and the 29th warrant (total issue price: 5.1 million yen, total issue price of stocks when issued
through exercising the stock acquisition rights: 500 million yen). Accordingly, Whiz Healthcare PE Series 1 Investment
Limited Liability Partnership completed payment of 1,005,100 thousand yen to the Company on January 15, 2013.
Additionally, the stock acquisition rights of the 29th warrant were partially exercised and the paid-in amount of 199,998
thousand yen had been received by the end of January 2013.
The Company made a resolution on November 19, 2013 regarding the issuance of new shares and secondary offering ofshares through a public offering and through a third party allotment. Accordingly, the payments of 2,503,744 thousand yen
and 321,118 thousand yen had been completed on December 4, 2013 and December 25, 2013, respectively.

-2-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013(iv) Business results
As a result of the above, net sales totaled 1,532,054 thousand yen for the fiscal year ended December 31, 2013, primarilyreflecting sales of SyB L-0501 in Japan and the other Asia Pacific territories. The net sales amount was decreased by 21.6%
compared to the previous year by following review of the current market inventory level of TREAKISYM®.
Selling, general and administrative expenses totaled 1,998,522 thousand yen (a year-on-year decrease of 12.9%),
including research and development (“R&D”) expenses of 1,052,790 thousand yen (a year-on-year decrease of 26.8%) due
to the accrual of expenses associated with the clinical trials for multiple indications for SyB L-0501, clinical trials for SyB
L-1101 and SyB C-1101, as well as other selling, general and administrative expenses of 945,731 thousand yen (a year-onyear increase of 10.6 %).
As a result, operating loss of 1,680,528 thousand yen was recognized for the fiscal year ended December 31, 2013
(operating loss of 1,700,273 thousand yen for the previous fiscal year). In addition, recording of amount totaling 35,363
thousand yen as non-operating expenses, primarily comprising commissions and stock-issuance expenses, and amount
totaling 114,467 thousand yen as non-operating income, primarily comprising foreign exchange gains, led to ordinary lossof 1,601,424 thousand yen (ordinary loss of 1,729,480 thousand yen for the previous fiscal year) and net loss of 1,605,224
thousand yen (net loss of 1,733,320 thousand yen for the previous fiscal year).
Segment information is omitted since the Company operates a single segment of pharmaceutical business including
research and development of pharmaceutical drugs as well as manufacturing, marketing and other related activities.
(Forecast for FY 2014)
We expect net sales of 1,785 million yen, a 16.5% increase from the fiscal year ended December 31, 2013, mainly due toincrease in sales of anticancer TREAKISYM® that has been on sale in Japan since December 2010. Meanwhile, for the aimof further enhancing the enterprise value, we will advance the development of proprietary pipelines, including new
indications for the mainstay anticancer drug SyB L-0501.To this end, we anticipate R&D expenses of 940 million yen(1,052 million yen in the previous fiscal year) and selling, general and administrative expenses of 2,083 million yen (1,998
million yen in the previous fiscal year) including R&D expenses.
The Company’s major development plans of pipelines are as follows:<SyB L-0501> (anticancer drug)
In addition to preparing for the Japanese submission for the indications of previously untreated indolent non-Hodgkin’s
lymphoma and mantle cell lymphoma, we plan to continue the Phase II clinical trial for the indication of chronic
lymphocytic leukemia.
<SyB L-1101 (intravenous formulation) and SyB C-1101 (oral formulation)> (anticancer drug)
We plan to continue the Japanese Phase I clinical trial of the intravenous formulation for the indication ofrefractory/relapsed MDS, and also the Japanese Phase I clinical trial of the oral formulation for the indication of previously
untreated MDS. We will also continue to look into the option of development for other indications.
As a result of these planned activities, net sales of 1,785 million yen, operating loss of 1,654 million yen, ordinary loss of
1,650 million yen, and net loss of 1,654 million yen are projected for FY 2014.

(2) Financial position analysis(Analysis of assets, liabilities, net assets, and cash flows)
Total assets as of December 31, 2013 stood at 7,686,947 thousand yen, an increase of 2,184,756 thousand yen from theprevious fiscal year end. This was primarily due to an increase of cash and deposits arising from issuance of new shares. Current
assets stood at 7,633,962 thousand yen, an increase of 2,213,338 thousand yen from the previous fiscal year end, reflecting an
increase of cash and deposits as well as marketable securities.
Total noncurrent assets stood at 52,985 thousand yen, a decrease of 28,582 thousand yen from the previous fiscal year end, due
to such factors as reclassification of current portion of advances paid to current assets and recording accumulated depreciation of
tangible and intangible fixed assets.
Liabilities stood at 253,950 thousand yen, a decrease of 348,281 thousand yen from the previous fiscal year end, reflecting adecrease of accounts payable-trade.
Under net assets, while retained earnings decreased by 1,605,224 thousand yen due to recording net loss, the total net assets
increased by 2,533,038 thousand yen from the previous fiscal year end to 7,432,996 thousand yen due to issuance of new shares-3-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

and new stock acquisition rights. As a result, the equity ratio increased by 6.8 percentage points from the previous fiscal year end
to 95.4%.
Cash and cash equivalents (hereinafter “cash”) stood at 5,294,137 thousand yen, an increase of 1,054,115 thousand yen fromthe previous fiscal year end. This was mainly due to a significant increase in cash from financing activities through issuance of
new shares, in spite of cash decrease from operating activities resulting from loss before income taxes, and of cash decrease frominvesting activities due to purchase of marketable securities with using funds procured through issuance of new shares.
Cash flows from each activity and its factors for this fiscal year end are as follows:(Cash Flow from Operating Activities)
Cash flow from operating activities showed an overall decrease of 1,677,348 thousand yen due to such decreasing factors as
net loss before tax of 1,601,424 thousand yen recorded and a decrease of accounts payable-trade by 329,768 thousand yen,despite such increasing factors as decreases of account receivables by 148,081 thousand yen and inventories by 39,662
thousand yen, and recognition of share-based compensation expense by 66,534 thousand yen.
(Cash Flow from Investing Activities)
Cash flows from investing activities showed a decrease of 1,332,254 thousand yen mainly due to the purchase of
marketable securities for 2,399,205 thousand yen and investing in time deposit for 1,138,419 thousand yen.
(Cash Flow from Financing Activities)
Cash flows from financing activities showed an increase of 4,056,658 thousand yen due to: (i) an issuance of new shares of
2,824,862 thousand yen, (ii) an issuance of corporate bonds with stock acquisition rights of 1,000,000 thousand yen and (iii)
issuance of new shares resulting from exercising stock acquisition rights of 241,598 thousand yen.
(Index trend related to cash flow)
5th Term

6th Term

7th Term

8th Term

9th Term

Fiscal year ended

Fiscal year ended

Fiscal year ended

Fiscal year ended

Fiscal year ended

December 2009

December 2010

December 2011

December 2012

December 2013

Equity ratio (%)

95.1

95.8

91.0

88.6

95.4

Equity ratio on a fair

―

―

126.0

104.3

151.4

―

―

―

―

―

―

―

―

―

―

market value basis (%)
Debt redemption period(years)Interest coverage ratio

Equity ratio: Equity (total shareholders’ equity) /total assets
Equity ratio on a fair market value basis: total market value of common stock/total assets
Debt redemption period: Interest-bearing debt/cash flow from operating activities
Interest coverage ratio: cash flow from operating activities/interest payment(Notes)
1. Equity ratio on a fair market value basis is not shown until the 6th term and is shown from the 7th term due tostock offering to the public.
2. Total market value was calculated based on the number of shares issued excluding treasury stocks.
3. Debt redemption period and interest coverage ratio are not available for the 5th Term and after due to negative
cash flow from operating activities.

(3) Basic policies concerning profit distribution and dividends
Since the foundation of the Company, dividends have not been distributed.
Although the Company started booking product sales, the Company develops pharmaceutical drugs and continues to use funds
for development activities. Therefore, it is our policy to attempt to gain retained earnings, not to distribute profit dividends, andpreference to retain funds for sustainable development activities. However, we recognize that the return of profit to stockholders
is an important management issue and will consider profit distribution based on future business performance and financial
condition.

-4-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

The articles of incorporation provide that the Company can pay interim dividend based on a corporate resolution by Board of
Directors on June 30 every year as the record date. The Company can also make a distribution of surplus by designating a record
date in addition to year-end and interim dividends. Decision making body is board of directors for interim dividend, shareholders'meeting for year-end dividend.

(4) Risks of business
Described below are major issues that may lead to potential risks in the Company's business activities. Issues that are notnecessarily considered significant by the Company are also disclosed, in view of our commitment to make active information
disclosure to investors and shareholders as these issues may carry weight in making investment decisions or in understanding ourbusiness activities. The Company is fully aware of the potential of these risks and will exert its utmost effort to prevent such risks
from substantiating, but should they substantiate, we intend to take full appropriate action. However, we consider that investment
decision regarding our stocks should be made by carefully evaluating the following matters, as well as other matters mentioned
in other sections of this document. We would add that the following descriptions do not purport to cover all possible risks
associated with investment in our stocks. The future perspectives mentioned below reflect our understanding of our businesscircumstances as of the date of publication of this document.
(i) Risks associated with pharmaceutical development in general
The Company's main business is to in-license drug development candidate compounds created by pharmaceuticalcompanies and bio ventures, and to develop them into pharmaceutical products. The R&D field of pharmaceuticals is repletewith strong competition including pharmaceutical giants. What is more, specialty pharmaceutical companies such as SymBio
try to emulate each other in quality and speed within the sector. The process from development to manufacture and marketing
involves many regulatory hurdles, necessitating a vast amount of capital input over a long period of time in business
operations. Their future prospects involve uncertainty and these risk factors are associated with the Company’s present andfuture business activities.
a) Uncertainty involved in pharmaceutical development
Generally speaking, the pharmaceutical development process up to the market launch of a drug requires a vast amount ofexpenditure over a long period. The probability of success is by no means high. In every stage of development, it is not
infrequent for a decision to be made to halt or delay progress. In pharmaceutical development, the different stages ofdevelopment have to be conducted in phases, and in each phase a decision is made on whether the development should
continue. Therefore, it is not rare to see a decision to stop a development in mid-process. The probability is low for adevelopment progressing successfully and for a product coming on stream. Even after a product is successfully developed
and launched in the market, there remains a risk that the approval gets cancelled because of inefficacy or side effects should
serious side effects prove to have the potential to increase damage to health (for details, refer to “(f) risk associated withside effects”), or should the efficacy fail to be recognized by the re-evaluation of efficacy and safety, conducted either on aregular or temporary basis, in light of the current academic standards of medicine and pharmaceuticals at the time of reevaluation. To reduce and spread these risks, the Company aims to possess several pipelines and endeavors to prioritize
insofar as possible the in-licensing of drug candidates with confirmed POC (Note 1) on human subjects. Yet, for small
specialty pharmaceutical companies such as SymBio, the impact is huge if a single candidate compound is removed fromthe pipeline. This could have a significant effect on our financial position, business performance, and cash flow.
(Note 1) POC (Proof of Concept) means confirming the efficacy and safety of a new drug candidate compound throughclinical trials and verifying the appropriateness of its concept.
b) Uncertainty of income
In order to raise income from the products we are developing, we need to succeed in all the stages of drug candidate
development, namely obtaining approval from regulatory authorities, manufacture and marketing either on our own or inpartnership with a third party. However, we may not necessarily succeed in these activities, or even if we do succeed, we
may not be able to ensure the sufficient profitability needed in continuing our business. Of the products currently in thedevelopment pipeline, the anticancer drug SyB L-0501 achieved approval for manufacturing and marketing in Japan on
October 27, 2010, for the indications of refractory/relapsed indolent non-Hodgkin's lymphoma and mantle cell lymphoma,
and in December 2010 it was launched as the anti-tumor agent TREAKISYM®. For additional indications, we havecompleted Phase II clinical trials on refractory/relapsed aggressive non-Hodgkin’s lymphoma, and are currently conducting
Phase II clinical trials on previously untreated indolent non-Hodgkin's lymphoma/mantle cell lymphoma, and chronic-5-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

lymphocytic leukemia. Furthermore, with respect to the anticancer agent rigosertib, Japanese Phase I clinical trials are being
initiated with the intravenous formulation, SyB L-1101, for the indication of refractory/relapsed myelodysplastic syndrome;
and with the oral formulation, SyB C-1101, for the indication of previously untreated myelodysplastic syndrome. We arepromoting the development of these compounds, aiming to successfully market the end products to obtain income. In somecases, we may consider entering into alliance with other pharmaceutical companies in development and marketing so as toexpedite the in-flow of income. Notwithstanding our effort, these pipeline compounds will take a considerable amount oftime before they reach the market. There is no guarantee that they will make it onto the market as viable products or that analliance agreement can be signed with other pharmaceutical companies. We are of the opinion that the selection ofindications and the methods of alliance and marketing so far identified promise sufficient future profitability, considering
the market size and marketing performance of approved drugs. However, should we prove to be wrong in the assessment, or
should there be any change in the conditions on which the assessment is based and we cannot promptly adjust to thechanges, there may be a significant impact on our financial position, business performance, and cash flow.
c) Uncertainly in legislations and regulations requiring compliance and health insurance system
The pharmaceutical industry, the Company‘s business field, is subject to various regulatory restrictions imposed by thepharmaceutical laws and administrative guidance as well as other relevant legislations of respective countries in all aspectsof business operations, namely, research, development, manufacture and marketing. We formulate our business plans inaccordance with the pharmaceutical laws and other current legislative regulations and with the health insurance system
together with the drug pricing developments that emerge from these legislations. Notwithstanding, there is a possibility thatthese regulations, systems and pricing will change before the products that we are developing reach the market. If any majorchange does occur, there may be a significant impact on our financial position, business performance, and cash flow.
d) Risk concerning development and marketing overseas
We conduct pharmaceutical business in Asia, not limited to Japan, where we anticipate growth of healthcare needs andposition as the strategic business domain. In overseas markets similarly to in Japan, the pharmaceutical development andmarketing generally require a vast amount of expenditure and are associated with business risks. To reduce investment
expenditure and spread business risks, we out-license the development and marketing of some of our developed drugs
overseas to pharmaceutical and other companies. When we out-licenses the rights we possess, we select a licensee company
after careful due diligence and continue monitoring as appropriate. The development and sales of out-licensed products are
subject to business conditions of the licensee company or any changes in regulatory and competitive environments in
respective countries and may fall below the original expectations, resulting in milestone revenue and royalty income
generated below our plan. In such cases, there may be an impact on our financial position, business performance, and cashflow.
e) Competition in the pharmaceutical industry
The pharmaceutical industry is an intensely competitive sector. A large number of both Japanese and foreign
pharmaceutical companies and research institutions including giant multinational pharmaceuticals compete in the arena.
Technological innovation is progressing rapidly. Many competitors have comparative advantage over us in technology,
marketing and financial position. Thus these companies may more efficiently produce and sell competitor products ofgreater effectiveness to our developed products. This means that what transpires in the competition we conduct with thesecompetitors in development, manufacturing and marketing operations may have a significant impact on our financial
position, business performance, and cash flow.
f) Risk associated with side effects
Unexpected side effects may occur from the use of pharmaceutical products, from their clinical trial stage to postmarketing stage. When serious and unexpected side effects are developed, compensation claims may arise, or depending on
the situation, there is the risk of a delay in clinical trials or even discontinuation of product development. In case such side
effects could lead to further damage to health, there is the risk for the cancellation of approval or the discontinuation ofsales. Regarding compensation claims, we have in place the liability insurance necessary to minimize the financial damage
when such claims arise. However, it does not exclude the possibility that the compensation award exceeds the amountinsured. If that happens, there may be a significant impact on our financial position, business performance, and cash flow.
g) Product liability-6-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

The development and manufacture of pharmaceutical products involve product liability risk. If in future, any productsthat we have developed cause damage to health or any inappropriate matters are discovered in clinical trials, manufacture,sales or marketing, we will be subject to product liability. This may have a significant impact on our financial position,business performance, and cash flow. Indeed, if a product liability compensation suit is filed against us, our corporate image
will be damaged, leading to loss of confidence in us and our drugs, which may have an impact on our business.
(ii) Risk in operating our businessa) Risk concerning business model
The Company does not own its research and manufacturing facilities. We mainly target orphan drugs (Note 2) in oncology,
hematology and autoimmune diseases, in-licensing from pharmaceutical companies and bio ventures drug candidates
mostly with POC confirmed on human subjects and developing and marketing them as pharmaceutical products for theJapanese and Asian markets (China, South Korea, Taiwan and Singapore, etc.). We adopt the business model to raise
income and profit from doing so. In developing the pipeline and marketing, we plan to engage in alliances with otherpharmaceutical companies. However, there is no guarantee that we can continuously in-license drug candidate compounds
that satisfy our criteria and secure these partner companies. In addition, as we mainly target orphan drugs for in-licensing
candidates (Note 3), we may not be able to generate the expected sales turnover. In such cases, there may be an impact on our
financial position, business performance, and cash flow. What is more, the competition surrounding the pharmaceuticalsector and changes in the Company's financial position may force us to revise our business model. Should this occur, there
may be a significant impact on our business.
(Note 2) The rare-disease field is one in which the need for medical treatment is great, but the numbers of patients requiring
drugs are small. Drugs for this field that are not undergoing rapid development are termed “orphan drugs”. In
order for the Japanese Ministry of Health, Labor and Welfare to designate a product as an orphan drug, thefollowing criteria must be met:i) It is used to treat a disease that affects less than 50,000 people in Japan,ii) There is a great need for medical treatment, andiii)The potential for development is high.
Designation as an orphan drug results in the following advantages: (a) the drug is given priority over otherproducts for regulatory review, reducing the time from regulatory submission to approval; (b) the re-examination
period can be extended up to 10 years; and (c) evaluation of an increased drug price can be expected.
(Note 3)“In-licensing candidates” are compounds for which an option investigated is that of obtaining from othercompanies the rights for development, etc., as the Company’s development candidates.
b) Dependency on a specific customer
As a specialty pharmaceutical company without production facilities, the Company needs to depend on supply of
products from other companies when conducting the clinical trials of products under development and in post-marketing
sales. Given this fact, the financial position and production conditions of the product supplier may have a significant impact
on our financial position, business performance, and cash flow. In pipeline development and marketing, our current
business plan is focused on forming alliances with pharmaceutical companies. However, if the partner company's
management condition deteriorates drastically or if its management policies change, which are matters beyond our control,
our initial business plan may not be realized. Also, if any breach of contract occurs that necessitate the termination of thecontract as stipulated by the contract, the alliance may end before the agreed term. In such cases, there may be a significant
impact on our financial position, business performance, and cash flow. Normally, in alliance contracts with partnercompanies, expected revenues of specialty pharmaceutical companies such as SymBio, to be gained before the products
reach the market will be a lump sum upon signing the contract, funding for co-development and milestone payment. Of
these, the milestone payment is an extremely unstable and unpredictable income as it is based on the attainment ofpredefined results. If development progress is delayed, there may be a significant impact on our financial position, businessperformance, and cash flow.
c) Risk concerning intellectual property rights
In our drug development activities, we make use of various intellectual property rights. The use of these rights basicallyhas been granted from other companies such as pharmaceuticals and ventures. However, the possibility remains that our inlicensed candidate compound does not succeed in the pending patent application made by the in-licensing partner.

-7-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

Moreover, it is difficult to completely avoid a third party creating an intellectual property right that supersedes theintellectual property right to which we have consent of use. These situations could lead to a significant impact on our
financial position, business performance, and cash flow. To date, no lawsuit has been filed by a third party against us
concerning intellectual property rights, including patents in connection with our product developments. When in-licensing a
product, we take advice from lawyers and conduct a thorough due diligence investigation through patent firms in order toreduce such intellectual property risks. Nevertheless, it is difficult to realize full protection from the occurrence ofintellectual property right disputes involving the infringement of third-party rights, and these may have a significant impact
on our financial position, business performance, and cash flow. The candidate compounds that we in-license are notnecessarily protected by patent. On the other hand, even if our candidate compound is not protected by patent, theassignment of the compound for review by the regulatory authorities would virtually restrict the entry of generic drugs
during the review period, realizing the monopolistic protection for a certain period of time.
d) Data protection
To reduce the risk of significant confidential information relating to pipeline development and other business activities
from leaking outside the company, the Company engages in rigorous data protection. We require directors, Scientific
Advisory Board (SAB) (Note 4) members, outsourcing partners, and other business partners to sign confidentiality agreements.
Even with the agreement in place, directors, SAB members, outsourcing partners and other business partners may notadhere to confidentiality, and should this occur, significant confidential information may be divulged elsewhere, which may
impact our business, financial position, business performance, and cash flow.
(Note 4) The Scientific Advisory Board (SAB) is an important evaluation body at the Company. On the basis of a large
number of Japanese and overseas new drug candidates, the SAB exchanges opinions and proposals about aportfolio that covers the risk/balance relationship with respect to medical needs and profitability, from theperspectives of various areas of expertise, discusses these thoroughly, and thus develops a strategy for thedevelopment pipeline. The Company convenes two or three SAB meetings per year, and invites Japanese andoverseas clinicians and scientists with high-level knowledge, expertise and experience to participate in these asadvisers with respect to exploratory research and new drug development.
e) Risk concerning important contracts
If any contracts that might have significant impact on conducting our business operations are terminated due to its
reaching full term, being cancelled or for any other reason, there may be a significant impact on our financial condition,business performance, and cash flow.
(iii) Risk associated with organizationa) Risk of being a young company
SymBio is a young company founded in March 2005.Since inception, we have engaged in in-licensing activities of drug
development candidate compounds. We built up the pharmaceutical development business from scratch and recorded
income from product sales in August 2010 for the first time in our history. There is a possibility that business issues that wehave not ever encountered arise in future. At the moment, however, it is difficult to predict any changes in the external
environmental factors that may affect our business results. Therefore, we consider our business results for the past years to
be inadequate reference material for passing an objective judgment on whether or not our company can continue to grow.
b) Risk of being a small corporation
The Company uses contract research organizations (CRO) in conducting R&D, thereby forming a development
framework requiring relatively small staff numbers. With progress in the development of pipeline already in place and withnew pipelines of new candidate compounds coming on stream, we plan to increase its human resources in R&D. However,for whatever reason, should an alliance with a CRO become terminated or should we fail to secure the planned number ofstaff or should the existing staff decide to leave, our business operations may be hampered, leading to a possible impact on
our financial position, business performance, and cash flow.
(Note 5) CRO(Contract Research Organization) is an organization that provides outsourcing services to the pharmaceuticalcompanies for their development of drugs without delay. The services include monitoring progress of clinical trial
protocols, managing clinical data and others.

-8-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013c) Dependency on a specific person
Mr. Fuminori Yoshida, the Representative Director, founding President and CEO, has played a key role since theCompany’s foundation in the implementation and execution of all operations in the company business management. Thus,in the event that Mr. Yoshida cannot continue to perform his corporate responsibilities for some unforeseen reasons, it will
have a significant impact on our business operations.
d) The Scientific Advisory Board (SAB)The Scientific Advisory Board (hereinafter “SAB”) is an advisory panel to the president on the in-licensing evaluation of
new drug candidates. We invite members of the panel from clinicians and scientists engaged in basic research who we
regard as having excellent track records and experience. The SAB meets two or three times a year to engage in active
discussion and debate, with each member giving his/her specialist perspective so that a good risk-balanced portfolio can becreated from among the vast volume of drug candidates gathered from the worldwide, with due consideration of healthcare
needs and profitability. We will continue in our effort to acquire members of excellence for the SAB. However, if difficulty
should arise in procuring members, for reasons such as the cancellation of contract with existing members, ending of theterm of office or refusal of renewal, or should a brain drain occur, there may be an impact on our in-licensing of drugcandidates.
(ix) Business Resultsa) Business performance in past years
The Company's key business indicators are given below
Term

5th Term

6th Term

7th Term

8th Term

9th Term

Fiscal Year Ended

December 2009

December 2010

December 2011

December 2012

December 2013

Net sales (thousandyen)

1,191,127

1,449,972

1,882,521

1,955,178

1,532,054

Operating income (loss)(thousand yen)

(208,027)(612,793)(2,066,846)(1,700,273)(1,680,528)

Ordinary income (loss)(thousand yen)

(214,072)(638,375)(2,095,382)(1,729,480)(1,601,424)

The Company’s net sales up until the 5th Term consisted only of income from alliance contracts (e.g. contract agreement
lump sum, milestone payment). From the 6th Term, we have recorded sales deriving from the sale of products. To date,with the exception of the 4th Term, the total R&D expenses and other general administrative expenses exceeded our
income, resulting in the posting of operating loss, ordinary loss and net loss. For this reason, we do not consider thefinancial statements and indicators for past years to provide adequate reference data in making timely comparisons inbusiness performance and in forecasting our future business performance.
b) Expected Increase in R&D Expenditure
The Company's R&D expenses for the past five fiscal years are given below
Term
Fiscal Year Ended
R&D expenses (thousandyen)

5th Term

6th Term

7th Term

8th Term

9th Term

December 2009

December 2010

December 2011

December 2012

December 2013

816,501

1,118,182

1,945,029

1,438,125

1,052,790

The Company intends to further continue R&D activities, which would mean an increase of the cumulative loss for theforeseeable future. With future increases in the product sales revenue from more additional indications of SyB L-0501 andin the income from alliances with pharmaceutical companies, we intend to improve our business performance as soon as
possible; however, there is no guarantee that our assumptions will materialize and swift performance improvement seen.
c) Negative balance of retained earnings brought forward
SymBio is a specialty pharmaceutical company. Until the products under development at the clinical stage reach themarket so that we can earn stable income through product sales and royalty income, we will post a huge up-front outlay of
R&D expenditure. Due to this, except 4th term (2008), we have posted net current losses since our foundation. At the end of-9-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

9th Term, the year ended December 31, 2013, we recorded negative balance of 8,751,636 thousand yen as retained earnings
carried forward.
We intend to become a profitable business entity as early as possible by advancing our quality clinical programs in a
rapid, precise and efficient manner as planned. However, the possibility still exists that profits may not be generated at thetime initially planned. Should our business fail to develop as planned and net profits are not generated, we face thepossibility of a considerable delay in our negative retained earnings carried forward turning positive.
d) Fund-raising
The nature of the Company's specialty pharmaceutical business means that the Company will require huge R&D funding.
If our business plan does not take shape as planned and we suffer a shortfall in funding, we will endeavor to procure funds
by changing our strategic alliances, securing new alliance contracts or issuing new stocks. However, if we fail to generate
funds exactly when they are required, there may be a serious doubt cast over the continuation of our business operations.
e) Net operating loss carried forward on tax
Net operating loss carried forward on tax exists this year end. For this reason, we are not subject to corporate tax, local
inhabitant tax and local enterprise tax at the standard rates and we expect this to continue for several terms into the future.
However, if our business performance makes a good progress in future due to favorable business development, net
operating loss carried forward may be removed earlier than anticipated and no longer be applied to the deduction of taxable
income. Should this situation occur, we would become liable for the payments of corporate tax, local inhabitant tax andlocal enterprise tax at standard rates, which may have an impact on net profit/loss and cash flow currently planned.
(v) Other Risksa) Profit distribution to stockholders
Since the foundation of the Company, dividends have not been distributed. We are currently at a business stage of still
making up-front investment into the development of pharmaceutical drugs and we continue to prioritize the use of funds forstrengthening our financial position and for continued R&D activities. Thus, we have at present no plans for making
dividend payout. However, we recognize that the return of profit to stockholders is an important management issue and willconsider profit distribution based on future business performance and financial condition.
b) Procurement of funds
As we rapidly expand our business, we expect to see an increase in our development funding requirement. One of ouroptions for procuring funds is to issue new stocks. If we do so, the number of our outstanding stock will increase,potentially diluting the value per share of our stock.
c) Stock value dilution by execution of stock acquisition rights
We adopt the stock option plan in order to motivate and encourage higher business performance of board directors,
employees, and collaborators, and to attract human resources of excellence. In accordance with the Commercial Code of1890 Article 280-19, 280-20 and 280-21, and Companies Act Article 236, 238, 239 and 240, stock acquisition rights are
granted to board directors and employees.
Moreover, the Company made a resolution at the Board of Directors meeting held on December 27, 2012 to issue thefirst unsecured convertible bond with stock acquisition rights (total issue price: 1 billion yen) and the 29th warrant (total
issue price: 5.1 million yen by way of third-party allotment, total issue price of stocks when issued through exercising thestock acquisition rights: 500 million yen). The proceeds from the issuance in the amount of 1,005,100 thousand yen were
paid in on January 15, 2013.
As of December 31, 2013, the number of potential dilutive shares from the above-mentioned stock acquisition rights(hereinafter “number of potential shares”) totals 3,444,150 shares and comprises approximately 10.1 % of the total numberof outstanding shares and potential shares added together.
There is the possibility that stock value per share for the company will be diluted if these potential shares are exercised in
the future. To attract talent, the Company may continue to offer similar incentives. This means that if these stockacquisition rights are exercised in future, the stock value per share of the company may be diluted.
d) Legal risk pertaining to unregistered offering of stock acquisition rights in the past
The Company has granted stock acquisition rights under the stock option plan as long-term incentives for board directors
and employees as well as collaborators since the foundation in March 2005.

- 10 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

Stock acquisition rights have been issued since the inception of plan paying special attention to a provision of Securities
and Exchange Law of 1948 that board directors and employees are excluded from the calculation of number of persons
receiving minority private offering. However, even after Order for Enforcement of the Financial Instruments and Exchange
Act Article 2-12 was no longer exempted (the article had purported to exempt the application of the provision that required
the exclusion of directors/officers and employees from the calculation of persons receiving small private offerings in casestock acquisition rights were granted to persons other than directors/officers and employees) due to the amendment of
Guidance for Corporate Information and Related Disclosure in response to the revision of Financial Instrument andExchange Act in September 2007, we had continued to issue stock acquisition rights in accordance with the provisions ofSecurities and Exchange Act 1948 due to the malfunction of internal organizations to collect information regarding revisionof laws and ordinances and assess their implications to the Company.
In consequence, it came to light that we had not duly submitted Securities Registration Forms for the stock acquisitionrights it had issued in October 2008, March 2009, and March 2010 despite there being legal obligations to do so as thenumber of persons receiving offers had exceeded 50, making them unregistered offerings prohibited under the laws.
Immediately upon discovery of this lapse, we reported the fact to the Kanto Local Finances Bureau and launched athorough enquiry into how and why such omission arose, and swiftly submitted the legally required disclosure documents
in August 2010. At the date of publication of this document, we have duly filed all the required disclosures.
Furthermore, based on in-house findings concurrently obtained regarding the cause of omission and advice received fromexternal experts, measures to prevent recurrence are formulated and put strictly in effect focusing on the following five
objectives: 1. Re-education regarding compliance at the whole company level, 2. Creation of compliance mechanism andinternal organization reinforcement, 3. Reinforcement of compliance committee functions, 4. Reinforcement of relations
with and active use of external experts, 5. Reinforcement of a system of checks by the board of auditors and internal audit
officeWe have not received any surcharge payment order related to this incident at the date of publication of this document.
Should we receive any surcharge payment order, however, it may have a significant impact on our financial position,business performance, and cash flow.
e) Stock holding by venture capitalIn general, venture capitals and investment partnerships own shares for the purpose of realizing capital gains by sellingshares after the IPO. There is the possibility that venture capitals and investment partnerships that own our shares may sell
all or a portion of our shares they own, and should it occur, it may have an impact on the market price of our share.
f) Risk of loss on foreign exchange
While continuously performing research on drug candidates for new development to expand its pipelines, the Company
arranges large amounts of fund procurements by means of deposits denominated in foreign currency or foreign exchange
contracts based on the assumption that the deposit payment in US dollars be required upon in-licensing. Where such assets
denominated in foreign currency are stated at market value on the financial statements at every year end, there is a risk ofloss from fluctuating currency valuation in the future and it may have an impact on our financial position, businessperformance, and cash flow.
g) Risk associated with natural disasters
If any disasters (earthquake, typhoon, fire, etc.) and plague occur in our geographic business domains, which lead to theoccurrence of human and material damage, or suspension and delay in business, fall in social credibility and compensation
issues may have an impact on our financial position, business performance, and cash flow.

2. Situation of corporate group
None to be reported.

3. Management policies(1) Basic policy of company management
SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida, who previously served concurrently
as Corporate VP of Amgen Inc. (Note 6) (United States) and President of Amgen K.K., a wholly owned subsidiary of Amgen Inc.,(currently Takeda Bio Development Center Limited) for 12 years since its founding stage.
We aim to achieve social and management responsibilities by responding to unmet medical needs (Note 7) with guiding principleof mutual harmony, spinning an intricate symbiotic relationship between patients, physicians, scientists, regulators and investors.

- 11 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

We regard underserved therapeutic areas with extremely significant medical needs as a business opportunity and focus on theareas of oncology, hematology, and autoimmune diseases where high entry barriers exist due to the high degree of specialization
required. In this sense, we are the first specialty pharmaceutical company (Note 8) in Japan. Rather than exploring blockbuster new
drugs (those with the sales of more than 100 billion yen), we channel our resources into the development of new drugs
specializing in oncology, hematology, and autoimmune diseases, where medical needs are outstanding though with the limited
market size. Holding multiple promising drugs and drug candidates in these areas will enable us to build the solid portfolio of
pipelines and continue our business sustainably.
(Note 6) Applied Molecular Genetics, or Amgen Inc., the world’s largest company in the biopharmaceutical field, wasfounded in Thousand Oaks, California, in 1980, and started business in Japan as Amgen K.K. on May 1, 1993. In
February 2008, Takeda Pharmaceutical Co., Ltd., obtained 100% of Amgen K.K.’s stocks, and the company nameis now “Takeda Bio Development Center Limited”(Note 7) “Unmet medical needs” means requirements for medical treatment that have not yet been fulfilled. It refers to asituation in which no effective drugs or treatments are currently available, despite strong demand by patients
and/or physicians.
(Note 8) “Specialty pharmaceutical company” refers to the company that develops new drugs and has been given a
consistently high international evaluation for a particular field of excellence. This is based on the definition in the
Ministry of Health, Labor and Welfare’s “Vision for the pharmaceutical industry” (2002).

(2) Key performance index
In order to enhance our enterprise value as a specialty pharmaceutical company, it is important to continually in-license
candidate drugs under development and proceed with the development to place the products on the market, and establish the saleand support system. To this end, we intend to aggressively make an ongoing investment of management resources into R&D
activities.
For the current fiscal year ended, we have recorded the net sales from SyB L-0501 for the first time since the drug wasapproved for sale in Japan and Singapore in 2010.
However, the product sales have not generated revenue enough to cover the aforementioned upfront investments at thismoment and net profit has yet to be realized. We continuously seek the early realization of a system to secure the stableprofitability by promoting TREAKISYM® in collaboration with Eisai, actively adding new indications for SyB L-0501, anddeveloping and acquiring an approval for other products in the pipeline.

(3) Pipeline
The Company currently has the following pipeline products under development: SyB L-0501, SyB L-1101 and SyB C-1101.
We will continue to in-license new candidate drugs so as to expand and build the pipeline portfolio with the balanced risk-return
trade-off.
(i) SyB L-0501
Bendamustine hydrochloride (the generic name), the active pharmaceutical ingredient of SyB L-0501, is an anticancer drugthat has been in use for a number of years in Germany under the trade name of Ribomustin for the treatment of non-Hodgkin's
lymphoma (Note 9), multiple myeloma, and chronic lymphocytic leukemia. We have elected to in-license this product because
there is currently no effective medication for the indications of refractory/relapsed indolent non-Hodgkin’s lymphoma andmantle cell lymphoma. These are precisely underserved therapeutic areas aligned with our corporate missions and also fallwithin one of our targeted therapeutic fields (hematologic cancer). Astellas Deutschland GmbH is the worldwide licensor of
bendamustine hydrochloride. In North America, Cephalon, Inc. (United States) is licensed from Astellas Deutschland GmbHand obtained approvals from Food and Drug Administration (FDA) in the United States to use the drug for the treatment ofchronic lymphocytic leukemia and refractory B-cell non-Hodgkin’s lymphoma in March 2008 and October 2008, respectively.
Mundipharma International Corporation Limited (United Kingdom) and Janssen-Cilag (United Kingdom) are also licensed
from Astellas Deutschland GmbH and have the exclusive rights for development and marketing for Europe and other regions,
respectively. Meanwhile, the Company is licensed from Astellas Deutschland GmbH and has the exclusive rights fordevelopment and marketing for Japan, China, South Korea and Singapore. In Japan, the drug received a manufacture andmarketing approval with the indications of refractory/relapsed indolent non-Hodgkin’s lymphoma and mantle cell lymphoma
on October 27, 2010 and came into market under the trade name of TREAKISYM® on December 10, 2010.

- 12 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

In addition, the Company is making progress with development for refractory/relapsed aggressive non-Hodgkin’s
lymphoma, previously untreated indolent non-Hodgkin’s lymphoma, mantle cell lymphoma and chronic lymphocytic
leukemia, as new indications. We intend to maximize the commercial value of bendamustine by further promoting life cycle
management. Eisai has signed a contract with us, giving it the rights of joint development and exclusive marketing for theJapanese market, and it is currently marketing TREAKISYM®.
In Asia, SyB L-0501 received the approval for the indication of indolent non-Hodgkin’s lymphoma and chronic
lymphocytic leukemia in Hong Kong in December 2009.In Hong Kong, Cephalon, Inc. has the exclusive rights fordevelopment and marketing and sells the drug. In addition, approval for the indications of indolent non-Hodgkin’s lymphoma
and chronic lymphocytic leukemia was achieved in Singapore in January 2010, and approval for the indications of chronic
lymphocytic leukemia and multiple myeloma was achieved in South Korea in May 2011.
In South Korea and Singapore, Eisai has contracts with us, giving it exclusive rights for development and marketing. Eisai
launched the product in Singapore and South Korea in September 2010 and October 2011, respectively.
Furthermore, Cephalon, our business partner, is making progress with clinical trials in China, and in Taiwan our business
partner InnoPharmax, Inc. (Taiwan), achieved approval on October 18, 2011, followed by the product launch in February
2012.
(Note 9) Non-Hodgkin’s lymphoma (NHL) is a cancer of lymphatic system in which lymphocytes develop malignant
growths other than Hodgkin’s lymphoma. The majority of Japanese patients are suffering from NHL.
Antibody therapy with rituximab (Note 10) administered as first-line drug is the standard treatment for NHL.
However, there is currently no established therapy for failed or relapsed cases.
(Note 10) Rituximab is an anti-CD20 monoclonal antibody used to treat the indication of CD20-positive B-cell non-Hodgkin
lymphoma. The formulation marketed in Japan is 10 mg/mL Rituxan® injection, with manufacturing andmarketing by Zenyaku Kogyo Co., Ltd., and sales by Chugai Pharmaceutical Co., Ltd.
(ii) SyB L-1101/ SyB C-1101
The drug with the generic name “rigosertib” has SyB L-1101 as the intravenous formulation, and SyB C-1101 as the oral
formulation, and is an anti-cancer agent with a unique type of multi-kinase inhibitory activity (note 11). It is currently being
developed in the USA and Europe by a US company, Onconova Therapeutics. Phase III clinical trials on the intravenous
formulation are underway for the indication of high-risk, refractory/relapsed MDS, and in 2009 the US Food and Drug
Administration designated rigosertib an orphan drug for this indication, and also agreed to special protocol assessment (SPA)(note 12)for the clinical trial protocol.
In addition, Onconova Therapeutics is making progress with development of an oral formulation of rigosertib, and Phase II

clinical trials are underway for the indication of low-risk, transfusion-dependent MDS.
In July 2011, the Company signed a license agreement with Onconova Therapeutics, providing us with the exclusive rightto develop and commercialize rigosertib in Japan and South Korea. Based on this agreement, we plan to make progress with
development of the intravenous rigosertib formulation for the indication of refractory/relapsed MDS, which development ismost advanced in the USA and Europe, and subsequently to make progress with development of the oral formulation for theindication of previously untreated MDS. MDS is the pre-pathological state for malignant tumors of blood cells, which haveshown increasing numbers of patients in recent years; it frequently affects elderly people; and it is a refractory disease, with ahigh probability of developing into leukemia. No effective medication is available yet, especially for refractory/relapsed MDS,
and it therefore constitutes an underserved therapeutic area.
While Onconova is making steady progress with development, we will look into the option of developing for indications
other than MDS. By allocating development of the oral and intravenous formulations to different indications, it is hoped that
progress will be made with development of treatment methods that are easy for patients to use, and that place sufficientimportance on the need for compliance.
(Note 11) Multi-kinase inhibitors impede the growth, proliferation and metastasis of cancer cells, thereby eradicating them.
(Note 12) SPA is a declaration from FDA after the end of Phase II clinical trials that an uncompleted Phase III clinical trial’s
design, indications, clinical endpoints, valuation items, and statistical analyses agreed upon at the pre-Phase III
meeting are acceptable for FDA approval. New drug licensing application utilizing this scheme facilitates theevaluation and approval by FDA and enhances the possibility of secure product launch in the market because FDA
already completes the considerations of the contents of Phase III clinical trials in advance.

- 13 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013(4) Medium to Long-term strategy
The Company is pursuing primarily the following five strategies in order to achieve our Long Range Plan (LRP).
(i) De-risking by post-POC strategy
We in-license drug candidates for which POC (proof of concept) is already confirmed on human subjects in principles.
Accordingly, they should be the drugs that are in a relatively late stage of clinical development or already on the market
overseas. The advanced development is already conducted overseas for these drug candidates and their efficacy and safety are
already confirmed on human subjects, thereby reducing the development risk. We utilize existing clinical data available
overseas so as to compress development timelines, reduce the development costs, and increase the likelihood of regulatory
approvals in Japan and Asian markets.
(ii) Building high-quality pipeline with exceptional search and evaluation capabilities
Our new drug search engine is connected to the diverse networks with pharmaceutical companies and bio ventures, andenables us to select promising drug candidates from the vast amount of chemical compounds after the careful review byinternal experts. Using their wealth of experience at the forefront of research and development, Scientific Advisory Board(SAB) members carefully evaluate and render final judgment on each drug candidate. The highly established screening
process up to the final selection of drug candidate, coupled with the post-POC strategy, reduces the development risk andcompresses the timelines. It also helps to understand how satisfactorily the healthcare needs are met and to improve theaccuracy of revenue projections after the product launch.
(iii) Containment of fixed costs by laboless/fabless strategy
The Company does not own any research or production facilities, which are often regarded as the main causes for fixed
costs. Once development candidate compounds are searched and selected, we focus on value-added activities such as theformulation and implementation of development strategy and outsource other necessary routines. This enables us to reduce
development costs of pharmaceutical drugs and secure the mobility of financial strategy.
(iv) Realization of high business efficiency by “Blue Ocean strategy” (Note 13)
There are many cases that the standard drug used overseas cannot be prescribed in Japan or a new drug is launched in Japan
five years behind its initial approval overseas. This problem is called “drug lag” and becoming aggravated, and the term like“cancer patient refugee” has been created. The drag lug is conspicuous in our strategic therapeutic areas of oncology,
hematology, and autoimmune diseases. The market of anticancer drugs is huge and still continues to grow with the population
being aged. However, anticancer drugs have a wide range of indications and they are fragmented by type of cancer. There is
only the limited number of patients in some therapeutic areas depending on type of cancer. Extremely high degree of
specialization is required for the development of anticancer drugs in these therapeutic areas, which are often financiallyunattractive for larger pharmaceutical companies to pursue despite the high degree of development difficulty. This partiallyaccounts for the causes for drug lag. Contrarily, once a new drug succeeds in receiving an approval and reaching the market
for these therapeutic areas, we would be able achieve a superior growth and profitability due to the lack of fierce competition
by continuously expanding the indications and bringing new products into the market.
(Note 13) “Blue Ocean strategy” means a strategy of redefining the market, avoiding marketplaces where there is fierce
competition to snatch pieces of a finite market-share “pie”, termed “red oceans”, and instead creating a “blueocean”, which is a competition-free, entirely unexploited market, enabling profits to be maximized while providing
customers with high-value products and services.
(v) Expanding Business in Asia Pacific Countries
Significant growth in medical needs and increasing demand for higher quality therapeutic options are expected in Asian
countries as they continue to undergo rapid economic development. Similar to in Japan, the trend observed is that thedevelopment of new drugs is stagnant with the population being rapidly aging in these countries. Indications in oncology,
hematology, and autoimmune diseases are emerging as areas of unmet medical needs with rising demand for effective
therapies. We secure the rights to manufacture and commercialize anticancer drugs SyB L-0501 and SyB L-1101/SyB C-1101
in Asian countries not only in Japan.

(5) Issues to be solved by the Company- 14 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

The Company will solve the following important issues:(i) Further expansion of pipeline
In order to enhance the enterprise value as a specialty pharmaceutical company, we need to expand the pipeline throughcontinually in-licensing of new candidate drugs for development.
Clinical trials are underway for our products: SyB L-0501 (anti-cancer drug), SyB L-1101 (the intravenous formulation)/C1101 (the oral formulation). We continue with ongoing efforts to in-license new products in order to expand our pipeline. In
addition, progress is currently being made with evaluation of several new candidate products.
(ii) Pursuit of life cycle management of TREAKISYM® (SyB L-0501) and rigosertib (SyB L-1101/ SyB C-1101)
In order to enhance the enterprise value, it is critical to maximize returns from each drug under development by adding new
indications for developed drugs after their initial introduction in pursuit of life cycle management.
TREAKISYM® has received the approval for manufacture and marketing with the approved indications ofrefractory/relapsed indolent non-Hodgkin’s lymphoma and refractory/relapsed mantle cell lymphoma. For additional
indications, Phase II clinical trials were completed for refractory/relapsed aggressive non-Hodgkin's lymphoma, and Phase II
clinical trials are underway for untreated indolent non-Hodgkin's lymphoma, untreated mantle cell lymphoma and untreatedchronic lymphocytic leukemia. Progress is being made with development of intravenous and oral rigosertib formulations forthe indication of myelodysplastic syndrome. No useful therapeutic agents are currently available for this indication, so it is anarea with very high unmet medical needs.
The aim for the future is to maximize the value of TREAKISYM® and rigisertib by further expansion of indications and byfollowing through with life-cycle management.
(iii) Expansion to other Asian regions
The Company positions China, South Korea, Taiwan, and Singapore as our important strategic geographic domains inaddition to Japan. In these areas, high growth in economy and medical needs is expected and we consider that these areas willassume increasing importance in our corporate strategy.
Among our pipelines, we plan to develop and market SyB L-0501 in China, South Korea, Taiwan, and Singapore as well asJapan. It is established by the result of market survey that significant medical needs exist for SyB L-0501 in these countries.
We also plan to develop and market SyB L-1101/ SyB C-1101 in South Korea other than Japan and currently consider
submitting the application for approval in South Korea. We will aggressively launch clinical trials on these drugs and apply formarketing approvals in these Asian countries.
(iv) Securing people
The Company places the highest priority on people as the company management resource. We cannot make superiorachievements in exploring and developing new drugs without talent. We have been continually recruiting talented people,
especially after going public, we have recruited the best and brightest people in order to strengthen the management
organization. Going forward, we plan to further strengthen our human resources by providing development programs such as
OJT and other trainings.
(v) Financial issue
It is necessary for the Company to raise funds required for business activities such as R&D expenditures as the pipeline
development progresses and the number of drug candidates increases. Therefore, we make every effort to strengthen thefinancial base by continually diversifying the method for fund procurement and reducing costs through and thorough budget
control.

(6) Other important matters concerning the Company’s management(i) Capital increase through a public offering and a third-party allotment
The Company made a resolution on November 19, 2013 regarding the issuance of new shares and the secondary offering of
the Company’s shares through a public offering and a third-party allotment in order to secure funds necessary for R&D
activities. The proceeds of 2,503,744 thousand and 321,118 thousand had been paid in on December 4, 2013 and December
25, 2013, respectively.

- 15 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

4．Financial statements(1) Balance sheets
FY 2012(as of December 31, 2012)
AssetsCurrent assets
Cash and deposits
Accounts receivable-tradeMarketable securities
Merchandise and finished goods
Supplies
Prepaid expenses
Advances paid
Consumption taxes receivable
Forward exchange contracts
Other
Total current assets
Noncurrent assets
Property, plant and equipment
Buildings
Accumulated depreciation
Buildings, net
Tools, furniture and fixtures
Accumulated depreciation
Tools, furniture and fixtures, net
Total property, plant and equipment
Intangible assets
SoftwareLease assets
Total intangible assets
Investments and other assets
Long-term prepaid expenses
Lease and guarantee deposits
Total investments and other assets
Total noncurrent assets
Total assets- 16 -(Unit: thousands of yen)
FY 2013(as of December 31, 2013)

4,540,022
148,081300,000
164,571320
98,192
99,03639,495
21,3859,517
5,420,623

6,163,231－
1,100,270
125,056173
64,30687,86232,552
52,438
8,072
7,633,962

7,705(5,067)
2,637
33,921(22,837)
11,084
13,721

7,705(5,260)2,444
33,921(27,733)
6,187
8,632

8,324
2,540
10,864

5,898
1,891
7,789

27,64629,33456,98081,567
5,502,190

9,427
27,13536,562
52,985
7,686,947

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

FY 2012(as of December 31, 2012)(Unit: thousands of yen)
FY 2013(as of December 31, 2013)

329,768
673
195,833
15,58856,662598,527－682
207,134
22,554
20,569250,941

2,017
1,688
3,705
602,232

1,334
1,675
3,009
253,950

6,024,610

8,058,860

5,994,610
5,994,610

8,028,860
8,028,860(7,146,411)(7,146,411)(17)
4,872,790(8,751,636)(8,751,636)(17)
7,336,067

－

167

－
27,167
4,899,957
5,502,190

167
96,761
7,432,996
7,686,947

Liabilities
Current liabilities
Accounts payable-trade
Lease obligations
Accounts payable-other
Income taxes payable
Other
Total current liabilities
Noncurrent liabilities
Lease obligations
Provision for retirement benefits
Total noncurrent liabilities
Total liabilities
Net assets
Shareholders' equity
Capital stock
Capital surplus
Legal capital surplus
Total capital surplus
Retained earnings
Other retained earnings
Retained earnings brought forward
Total retained earnings
Treasury stock
Total shareholders' equity
Valuation and translation adjustments
Valuation difference on available-for-salesecurities
Total valuation and translation adjustments
Stock acquisition rights
Total net assets
Total liabilities and net assets- 17 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

(2) Statements of operations

Net sales
Net sales of goods
Rights income
Total net sales
Cost of sales
Beginning goods
Cost of purchased goods
Purchase allowance and returns
Total
Transfer to other account *3
Ending goods
Cost of goods sold
Gross profit
Selling, general and administrative expenses *1, 2, 3
Operating loss
Non-operating income
Interest income
Interest on securities
Foreign exchange gain
Insurance and dividends income
Other
Total non-operating income
Non-operating expenses
Interest expenses
Commission fee
Stock issuance cost
Bond-issue expenses
Foreign exchange loss
Other
Total non-operating expenses
Ordinary loss
Extraordinary loss
Loss on retirement of noncurrent assets *4
Total extraordinary losses
Loss before income taxes
Income taxes-current
Total income taxes
Net loss- 18 -FY 2012(from January 1, 2012
to December 31, 2012)(Unit: thousands of yen)
FY 2013(from January 1, 2013
to December 31, 2013)

1,955,178－
1,955,178

1,432,054
100,000
1,532,054

207,467
1,321,514－
1,528,982
2,211
164,571
1,362,199
592,979
2,293,253(1,700,273)

164,571
1,175,305
759
1,339,117－
125,056
1,214,061
317,993
1,998,522(1,680,528)

1,585
3,353
－
1,122
1,247
7,309

7,030
3,003
97,593
1,104
5,733
114,467

137
10,829－9,473
15,755320
36,516(1,729,480)

31
10,734
23,383100－
1,113
35,363(1,601,424)

39
39(1,729,520)
3,800
3,800
(1,733,320)－－(1,601,424)
3,800
3,800
(1,605,224)

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013(3) Statements of changes in net assets
FY 2012 (from January 1, 2012 to December 31, 2012)(Unit: thousands of yen)

Capitalstock

Balance at the
beginning of the year
Changes of items during
the year
Net loss
Net changes of items
other thanshareholders' equity
Total changes of
items during the year
Balance at the end of
the year

6,024,610

Shareholders' equity
Capital surplus
Retained earnings
Otherretainedearnings
Legal
Total
Total
capitalcapitalretained
Retained
surplussurplusearnings
earnings
brought
forward5,994,610

5,994,610 (5,413,091) (5,413,091)

6,606,110(1,733,320)－ (1,733,320)－－－ (1,733,320) (1,733,320)

6,024,610

5,994,610

5,994,610 (7,146,411) (7,146,411)(Unit: thousands of yen)

Valuationdifferenceonavailablefor-salesecurities

Total
valuationandtranslation
adjustments

StockacquisitionrightsTotal net
assets

(546)

(546)

－

6,605,564(1,733,320)
546

546

27,167546

546

27,167 (1,705,606)－－

27,167- 19 -(17)(1,733,320) (1,733,320)

Valuation and translation
adjustments

Balance at the
beginning of the year
Changes of items during
the year
Net loss
Net changes of items
other thanshareholders' equity
Total changes of
items during the year
Balance at the end of
the year

Total
Treasuryshareholders’stockequity27,713

4,899,957(17)

4,872,790

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

FY 2013 (from January 1, 2013 to December 31, 2013)(Unit: thousands of yen)
Shareholders' equity
Retained earnings
Otherretainedearnings
Total
Total
capitalretained
Retained
surplusearnings
earnings
brought
forwardCapital surplus

Balance at the
beginning of the year
Changes of items during
the yearIssuance of new shares
Net loss
Net changes of items
other thanshareholders' equity
Total changes of
items during the year
Balance at the end of
the year

Capital
stock

Legal
capitalsurplus6,024,610

5,994,610

5,994,610 (7,146,411) (7,146,411)

2,034,250

2,034,250

2,034,250(17)

4,872,790

4,068,501(1,605,224)(1,605,224) (1,605,224)

2,034,250

2,034,250

2,034,250 (1,605,224) (1,605,224)－

2,463,276

8,058,860

8,028,860

8,028,860 (8,751,636) (8,751,636)(17)

7,336,067(Unit: thousands of yen)
Valuation and translation
adjustments

Balance at the
beginning of the year
Changes of items during
the yearIssuance of new shares
Net loss
Net changes of items
other thanshareholders' equity
Total changes of
items during the year
Balance at the end of
the year

Total
Treasuryshareholders’stockequityValuationdifferenceonavailablefor-salesecurities

Total
valuationandtranslation
adjustments

StockacquisitionrightsTotal net
assets－－27,167

4,899,957

4,068,501(1,605,224)
167

167

69,594

69,761

167

167

69,5942,533,038

167

167

96,761

7,432,996- 20 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013(4) Statements of cash flows
FY 2012(from January 1, 2012
to December 31, 2012)
Net cash provided by (used in) operating activities
Loss before income taxes
Depreciation
Amortization of guarantee deposits
Share-based compensation expenses
Increase (decrease) in provision for retirement benefits
Interest income
Interest expenses
Gain on sale of marketable securities
Foreign exchange losses (gains)
Stock issuance cost
Commission fee
Loss on retirement of noncurrent assets
Decrease (increase) in accounts receivable-trade
Decrease (increase) in inventories
Decrease (increase ) in prepaid expenses
Decrease (increase) in advances paid
Decrease (increase) in consumption taxes receivable
Decrease (increase) in other current assets
Decrease (increase) in long-term prepaid expenses
Increase (decrease) in accounts payable-trade
Increase (decrease) in accounts payable-other
Increase (decrease) in advances received
Increase (decrease) in other current liabilities
Other
SubtotalInterest and dividends income received
Commitment fees paid
Interest expenses paid
Income taxes paid
Net cash provided by (used in) operating activities
Net cash provided by (used in) investing activities
Decrease (increase) in time deposits
Proceeds from withdrawal of time deposits
Purchase of marketable securities
Proceeds from redemption of securities
Proceeds from sale of marketable securities
Purchase of property, plant and equipment
Purchase of intangible assets
Payments for lease and guarantee deposits
Proceeds from collection of lease and guarantee
deposits
Net cash provided by (used in) investing activities- 21 -(1,729,520)
8,560
1,444
27,167(404)(4,938)
137
－
1,630
－
10,82939
14,32842,575(19,183)
25,55230,076(6,835)(3,346)
20,814(82,105)(1,382)
15,458291(1,648,808)
4,917(10,800)(96)(3,800)(1,658,588)(300,000)－(300,000)
200,000－(1,858)(1,190)(8,105)(Unit: thousands of yen)
FY 2013(from January 1, 2013
to December 31, 2013)(1,601,424)
8,163
1,829
66,534(13)(10,034)
31(5,354)(37,733)
23,383
10,734－148,081
39,66232,751
11,174
6,943(26,743)
18,219(329,768)
2,037－(29,221)100(1,670,646)
6,729(9,600)(31)(3,800)(1,677,348)(1,138,419)
600,000(2,399,205)
1,100,000
505,000
－
－
－

590

370

(410,563)(1,332,254)

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

Net cash provided by (used in) financing activities
Proceeds from issuance of stock resulting from exerciseof stock acquisition rights
Proceeds from issuance of bonds with stock acquisitionrightsProceeds from issuance of stock acquisition rights
Payments for issuance of common stock
Proceeds from issuance of common stock
Repayments for lease obligations
Other payments
Net cash provided by (used in) financing activities
Effect of foreign exchange rate change on cash and cash
equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year *- 22 -FY 2012(from January 1, 2012
to December 31, 2012)(Unit: thousands of yen)
FY 2013(from January 1, 2013
to December 31, 2013)－

241,598－

1,000,000

－
－
－
(719)
－
(719)

5,100
(14,119)2,824,862
(682)
(100)
4,056,658(1,084)

7,059(2,070,956)
6,310,9784,240,022

1,054,115
4,240,022
5,294,137

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

(5) Events and conditions with indicate there could be substantial doubt about going concern assumption
None to be reported.

(6) Significant accounting policies
1.

Valuation basis and method of marketable and investment securities
Available-for-sale securities with determinable market value
Available-for-sale securities with a determinable market value are stated at fair value with any changes in
unrealized holding gain or loss, net of applicable income taxes, included directly in shareholders’ equity.
Cost of securities sold is calculated by the moving average method.
Available-for-sale securities without determinable market value
Available-for-sale securities without determinable market value are stated at cost determined by themoving average method.

2.

Valuation basis and method of derivative transactions
Derivative financial instruments are stated at fair value.

3.

Valuation basis and method of inventories
Inventories held for the purpose of ordinary sale are measured at lower of cost determined by the weightedaverage method or net selling value.

4.

Depreciation of property, plant and equipment(1) Property, plant and equipment (excluding lease assets)
Depreciation of property, plant and equipment is computed by the straight-line method.
The useful lives of major property, plant and equipment are summarized as follows:
Buildings
2 to 18 years
Tools, furniture and fixtures
4 to 10 years(2) Intangible assets (excluding lease assets)
Amortization of intangible assets is computed by the straight-line method.
Capitalized software costs are being amortized over the period of the internal use of 5 years.
(3) Lease assets
Depreciation of lease assets is computed by the straight-line method over the lease term with no residual
value.

5.

Deferred assets(1) Stock issuance costs are charged to income as incurred.
(2) Bond-issue expenses are charged to income as incurred.

6.

Foreign currency translation
Monetary assets and liabilities denominated in foreign currencies are translated into yen at the spot exchange
rates prevailing at the balance sheet dates, and resulting gains or losses are credited or charged to income.

7.

Basis for reserves and provisions(1) Allowance for doubtful accounts
The allowance for doubtful accounts is provided at an amount determined based on the historicalexperience of bad debt with respect to ordinary receivables and an estimate of uncollectible amounts
determined by reference to specific doubtful receivables from customers which are experiencing financial
difficulties.
For FY2013, no allowance for doubtful accounts is provided due to no historical experience of bad debt
and no receivable balances that are deemed uncollectible.
(2) Provision for retirement benefits
The provision for retirement benefits is provided at an amount to be required as of the balance sheet date.

8.

Cash and cash equivalents in the statements of cash flows
Cash and cash equivalents consist of cash on hand, cash in banks which can be withdrawn at any time andshort-term investments with a maturity of three months or less that can easily be converted to cash and are
subject to little risk of change in value.
- 23 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

9.

Other significant basis for the preparation of financial statements
Accounting for consumption tax
Transactions are recorded at amounts exclusive of consumption tax.

(This part is intentionally left blank)- 24 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

(7) Notes to financial statements(Balance sheets)
1. The Company has overdraft and commitment line contracts with three banks in a business relationship to efficiently
procure working capital. The status of the bank overdraft and loan commitments based on these contracts at the end ofeach fiscal year is as follows:(Unit: thousands of yen)
FY 2012(as of December 31, 2012)
Total amounts of bank overdraft limit andloan commitment line
Balance of borrowing outstanding
Unused balance

FY 2013(as of December 31, 2013)

1,350,000

1,350,000－
1,350,000－
1,350,000(Statements of operations)* 1 Selling expense ratio is roughly 2.1% and 1.5% for FY 2012 and FY 2013, respectively, and administrative expense
ratio is roughly 97.9% and 98.5 % for FY 2012 and FY 2013, respectively.
Major expense items and amounts are as follows.
(Unit: thousands of yen)
FY 2012(from January 1, 2012
to December 31, 2012)

FY 2013(from January 1, 2013
to December 31, 2013)

106,108
305,679921
1,438,125
6,990

124,067
316,434811
1,052,790
6,639

Directors’ compensation
Salaries
Retirement benefit expenses
Research and development expenses
Depreciation expenses*2*3

Total amounts of research and development expenses included in general and administrative expenses(Unit: thousands of yen)
FY 2012(from January 1, 2012
to December 31, 2012)

FY 2013(from January 1, 2013
to December 31, 2013)

1,438,125

1,052,790

Details of transfer to other accounts are as follows.
(Unit: thousands of yen)
FY 2012(from January 1, 2012
to December 31, 2012)

Selling, general and administrative expenses*4

FY 2013(from January 1, 2013
to December 31, 2013)
－

2,211

Details of loss on retirement of noncurrent assets are as follows.
(Unit: thousands of yen)
FY 2012(from January 1, 2012
to December 31, 2012)39

Software- 25 -FY 2013(from January 1, 2013
to December 31, 2013)－

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

(Statements of changes in net assets)
FY 2012 (from January 1, 2012 to December 31, 2012)
1. Shares issued and outstanding / Treasury stock(Unit: number of shares)
At the beginning of
the fiscal year

IncreaseAt the end of the
fiscal year

Decrease

Shares issued
Common stockTotal

19,130,900－－

19,130,900

19,130,900－－

19,130,900

75

－

－

75

75

－

－

75

Treasury stock
Common stock
Total

2. Stock acquisition rights and treasury acquisition rights
Balance
as ofDecemberAt the end of 31, 2012
Decrease
the fiscal (thousands
yearof yen)Number of shares to be issued
Company

Type ofshares to beissuedDescription

The
Stock acquisition rights
Company as stock options

At thebeginning of
the fiscal
year

Increase

－

－

－

－

27,167－－－－

27,167―

Total(Note) The information about type of shares to be issued and the number of shares to be issued is described in “Stock
options.”
3. Dividends
None to be reported.
FY 2013 (from January 1, 2013 to December 31, 2013)
1. Shares issued and outstanding / Treasury stock(Unit: number of shares)
At the beginning of
the fiscal year

IncreaseAt the end of the
fiscal year

Decrease

Shares issued
Common stockTotal

19,130,900

11,503,357－

30,634,257

19,130,900

11,503,357－

30,634,257

75

－

－

75

75

－

－

75

Treasury stock
Common stock
Total(Note) The increase in common stock of 11,503,357 shares consisted of: (i) an increase of 3,921,257 shares due toexercise of stock acquisition rights, (ii) an increase of 6,720,200 shares due to issuance of new shares throughthe public offering and (iii) an increase of 861,900 shares due to issuance of new shares through the third party
allotment.

- 26 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

2. Stock acquisition rights and treasury acquisition rights
Balance
as ofDecemberAt the end of 31, 2013
Decrease
the fiscal (thousands
yearof yen)Number of shares to be issued
Type ofshares to beissuedAt thebeginning of
the fiscal
year

Increase

The
Stock acquisition rights
Common stock
Company as stock options

－

－

－

－

93,701

Total

－

－

－

－

93,701Company

Description(Note) The information about type of shares to be issued and the number of shares to be issued is described in “Stock
options.”
3. Dividends
None to be reported.

(Statements of cash flows)* Cash and cash equivalents as of the fiscal year end are reconciled to the accounts reported in the balance sheets asfollows:(Unit: thousands of yen)
FY 2012(from January 1, 2012
to December 31, 2012)
Cash and deposits
Marketable securities
Time deposits with maturities of more than three months
Debt securities with a remaining maturity in excess of
three month
Cash and cash equivalents

FY 2013(from January 1, 2013
to December 31, 2013)

4,540,022
300,000(300,000)

6,163,231
1,100,270(869,093)(300,000)(1,100,270)

4,240,022

5,294,137(Lease transactions)
Finance lease transaction
Finance lease transactions other than those which transfer the ownership of leased property(1) Description of lease assets
Intangible assets ---Software(2) Depreciation and amortization of lease assets
Depreciation and amortization of lease assets is described in significant accounting policies “4. Depreciation ofproperty, plant and equipment.”- 27 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

(Financial instruments)
1. Financial instruments(1) Policies for financial instruments
The Company procures the funds necessary in light of the pipeline development plan (primarily by third-party
allotment and offering by new stock issuance). Temporary surplus fund is invested in financial instruments which
are highly safe and liquid.
As a principle, the Company does not enter into derivative transactions for speculative trading purpose but uses
them within the scope prescribed in the internal rules.
(2)Types of financial instruments and related risks
Operating receivables such as accounts receivable-trade and advances paid in connection with joint development
are exposed to credit risk of customers and joint development partners. Operating receivables denominated inforeign currencies are exposed to foreign exchange fluctuation risk.
The Company intends to invest in marketable and investment securities which have relatively low risk of falling
below initial investments. However, it might carry a finite risk.
Operating payables such as accounts payable-trade and accounts payable-other are mostly due within twomonths. Operating payables denominated in foreign currencies are exposed to foreign exchange fluctuation risk.
The Company uses derivative transactions to avoid foreign exchange fluctuation risks and enters into forward
exchange contracts within the scope prescribed in the internal rules based on balances of receivables and payables
denominated in foreign currencies as well as actual volume of exports and imports transactions denominated inforeign currencies.
Lease and guarantee deposits are mostly security deposits related to rented office premises and their refunds are
subject to the credit risk of the lessor.
Lease obligations are associated with the finance lease transactions that intend to finance capital expenditures
and the longest maturity of lease term is 3 years after December 31, 2013.
(3)Risk management for financial instruments(i) Monitoring of credit risks (the risk that customers or counterparties may default)
In accordance with the internal credit policies for managing credit risk arising from operating receivables,
the Company’s marketing department periodically monitors the credit worthiness of major customers andmonitors due dates and outstanding balances by individual customer. In addition, the Company is making
efforts to promptly identify and mitigate risks of bad debts from customers who are having financial
difficulties.
The Company enters into derivative transactions only with financial institutions which have a sound credit
profile in order to mitigate the counterparty risk.
(ii) Monitoring of market risk (the risk arising from fluctuations in foreign exchange rates, interest rates andothers)The Company deposits cash primarily with financial institutions with high credit ratings.
For marketable and investment securities, the Company intends to avoid risks of falling below initialinvestments by investing in securities with the satisfactory credit rating and investment period in accordancewith the internal investment policies.
The Company enters into forward exchange contracts in order to avoid foreign exchange fluctuation risks inconnection with receivables and payables denominated in foreign currencies.
Followed by appropriate authorization procedures prescribed in the internal rules, Finance & Accounting,Corporate Planning Group executes and monitors derivative transactions. Monthly transaction performances
are reported to the executive management committee.
(iii) Monitoring of liquidity risks (the risk that the Company may not be able to meet its obligations on scheduled
due date)
Based on the report from each department, the responsible department of the Company prepares and updates
its cash flow plans on a timely basis and ensures to maintain liquidity on hand to manage liquidity risk.
- 28 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013(4) Supplementary explanation of the estimated fair value of financial instruments
The fair value of financial instruments is based on their quoted market price, if available. When there is noquoted market price available, fair value is reasonably estimated. Since various assumptions and factors arereflected in estimating the fair value, different assumptions and factors could result in different fair value. In
addition, the notional amounts of derivatives in notes to “Derivative transactions” are not necessarily indicativeof the actual market risk involved in derivative transactions.
(5) Concentration of credit risk
As of December 31, 2013, all operating receivables are from one particular major customer.
2. Fair value of financial instruments
Carrying value on the balance sheets, fair values and their differences are as follows. The financial instruments
whose fair value is extremely difficult to determine are not included. (See (Note) 2.)
FY 2012 (as of December 31, 2012)(Unit: thousands of yen)
Carrying value

Fair value

Differences

4,540,022

4,540,022－(2) Accounts receivable-trade148,081

148,081－(3) Marketable securities

300,000

300,000－(4) Advances paid

99,03699,036－(5) Consumption taxes receivable

39,49539,495－

5,126,635

5,126,635－

329,768

329,768

－

673

678

4

(3) Accounts payable-other

195,833

195,833－(4) Income taxes payable

15,58815,588－(5) Lease obligations (non-current)

2,017

2,023

5

Liabilities, total

543,882

543,892

10

Derivative transactions, total (*1)

21,385

21,385－(1) Cash and deposits

Assets, total(1) Accounts payable-trade(2) Lease obligations (current)(* 1) Net assets and liabilities arising from derivative transactions are presented on a net basis.

- 29 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

FY 2013 (as of December 31, 2013)(Unit: thousands of yen)
Carrying value

Fair value

Differences

6,163,231

6,163,231

－

―

―

－

1,100,270

1,100,270－(4) Advances paid

87,862

87,862－(5) Consumption taxes receivable

32,55232,552－

7,383,915

7,383,915－(1) Accounts payable-trade

―

―

－

(2) Lease obligations (current)

682

683

0

(3) Accounts payable-other

207,134

207,134－(4) Income taxes payable

22,55422,554－(5) Lease obligations (non-current)

1,334

1,334

0

Liabilities, total

231,706

231,7070

Derivative transactions, total (*1)

52,43852,438－(1) Cash and deposits(2) Accounts receivable-trade(3) Marketable securities

Assets, total(* 1) Net assets and liabilities arising from derivative transactions are presented on a net basis.
(Note)
1. Fair value measurement of financial instruments and other matters related to securities and derivative transactions
Assets(1) Cash and deposits, (2) Accounts receivable-trade, (4) Advances paid and (5) Consumption taxes receivable
The carrying value is deemed as the fair value since these are scheduled to be settled in a short period oftime.
(3) Marketable securities
The fair value of debt securities is based on the quoted price obtained from financial institutions. Seenotes to “Marketable and investment securities” for notes pertaining to securities by holding purpose.
Liabilities(1) Accounts payable-trade, (3) Accounts payable-other and (4) Income taxes payable
The carrying value is deemed as the fair value since these are scheduled to be settled in a short period oftime.
(2) Lease obligations (current) and (5) Lease obligations (non-current)
The fair value of lease obligations, that is determined at present value calculated by discounting total
amounts of principle and interests at a presumable rate used for similar new lease transactions.
Derivative transactions
See notes to “Derivative transactions.”- 30 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

2. Financial instruments whose fair value is extremely difficult to determine(Unit: thousands of yen)
FY 2012(as of December 31, 2012)
Lease and guarantee deposits

FY 2013(as of December 31, 2013)

29,334

27,135

Lease and guarantee deposits are not included in above tables since no market quote is available and their fairvalue is extremely difficult to determine.
3. The redemption schedule for monetary assets and securities with maturities
FY 2012 (as of December 31, 2012)(Unit: thousands of yen)
Due after one
Due after fiveDue in one year
Due after ten
year through five years through ten
or less
years
years
years
4,539,915－－－

Deposits

148,081－－－(1) Others

300,000－－－

Advances paid

99,036－－－

5,087,032－－－

Accounts receivable-trade
Securities
Available-for-securities with maturities
Debt securities

Total

FY 2013 (as of December 31, 2013)(Unit: thousands of yen)
Due after fiveDue after one
Due after ten
Due in one year
year through five years through ten
years
or less
years
years
－
－
－
6,163,194

Deposits
Securities
Available-for-securities with maturities
Debt securities(1) Corporate bond
Other
Advances paid
Total

499,940－－－

600,330－－－

87,862－－－

7,351,326－－－- 31 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

4. Maturities of lease obligations after the fiscal year end
FY 2012 (as of December 31, 2012)

Due in one
year or lessLease obligations(current)
Lease obligations(non-current portion)
Total

Due after one
year throughtwo years(Unit: thousands of yen)
Due after two Due after three Due after four
Due after five
years through years through years throughyears
five years
four years
three years

673

－

－

－

－

－

－

682

692

642

－

－

673

682

692

642

－

－

FY 2013 (as of December 31, 2013)

Due in one
year or lessLease obligations(current)
Lease obligations(non-current)
Total

Due after one
year throughtwo years(Unit: thousands of yen)
Due after two Due after three Due after four
Due after five
years through years through years throughyears
five years
four years
three years

682

－

－

－

－

－

－

692

642

－

－

－

682

692

642

－

－

－

- 32 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013(Marketable and investment securities)
1. Available-for-sale securities
FY 2012 (as of December 31, 2012)(Unit: thousands of yen)Type

Carrying value

Acquisition cost

－

－

－

(a) Government andmunicipal bond

－

－

－

(b) Corporate bond

－

－

－

300,000

300,000

－

－

－

－

300,000

300,000－(1)Equity securities

Difference(2)Debt securities
Carrying value does notexceed the acquisition cost(c) Other(3)OtherTotal
FY 2013 (as of December 31, 2013)(Unit: thousands of yen)Type

Carrying value

Acquisition cost

Difference

－

－

－

(a) Government andmunicipal bond

－

－

－

(b) Corporate bond

－

－

－

(c) Other－－－

600,330

600,000

330

600,330

600,000

330

－

－

－

(a) Government andmunicipal bond

－

－

－

(b) Corporate bond

499,940

500,000

(60)

－

－

－

－

－

－

499,940

500,000(60)(1)Equity securities(2)Debt securities

Carrying value exceeds theacquisition cost(3)Other
Total(1)Equity securities(2)Debt securities
Carrying value does notexceed the acquisition cost(c) Other(3)OtherTotal- 33 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

2. Available-for-sale securities soldFY 2012 (from January 1, 2012 to December 31, 2012)(Unit: thousands of yen)Type

Proceeds

Realized gains

Realized losses

－

－

－

(a) Government andmunicipal bond

－

－

－

(b) Corporate bond

－

－

－

(c) Other－－－

1,853,428－－

1,853,428－－(1)Equity securities(2)Debt securities(3)OtherTotal

FY 2013 (from January 1, 2013 to December 31, 2013)(Unit: thousands of yen)Type

Proceeds

Realized gains

Realized losses

－

－

－

(a) Government andmunicipal bond

－

－

－

(b) Corporate bond

505,000

5,354

－

－

－

－

－

－

－

505,000

5,354－(1)Equity securities(2)Debt securities(c) Other(3)Other
Total(Derivative transactions)
1. Derivative transactions to which hedge accounting is not applied
Currency-related transaction
FY 2012 (as of December 31, 2012)(Unit: thousands of yen)Classification

Type

Portion due
Notional amount after one year
includedhereinFair value

Unrealized gain

Forward exchange contract
OTC transactions

Buy
Euro
Total

(Note)

242,027－

21,385

21,385

242,027－

21,385

21,385

Fair value measurement
The fair value is measured based on the quoted prices obtained from financial institutions with business
relationship.
- 34 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

FY 2013 (as of December 31, 2013)(Unit: thousands of yen)Classification

Type

Portion due
after one year
Notional amount included
hereinFair value

Unrealized gain

Forward exchange contract
OTC transactions

Buy
US dollar

81,004

－

3,260

3,260

Euro

635,710－

49,17749,177

716,714－52,43852,438

Total(Note)

Fair value measurement
The fair value is measured based on the quoted prices obtained from financial institutions with business
relationship.

2. Derivative transactions to which hedge accounting is applied
None to be reported.

(Retirement benefits)
1. Outline of retirement benefit plans
The Company has adopted a lump-sum payment plan as a defined benefit plan and a defined contribution pension
plan as a defined contribution plan.
2. Retirement benefit obligation(Unit: thousands of yen)
FY 2012FY 2013(as of December 31, 2012) (as of December 31, 2013)(1) Retirement benefit obligation(1,688)(1,675)(2) Provision for retirement benefits(1,688)(1,675)(Note)The simplified method is applied to calculate amounts of retirement benefit obligation. That is, the amounts
shown as retirement benefit obligation are the payments required for voluntary retirement as of each fiscal
year end.

3. Retirement benefit expenses(Unit: thousands of yen)
FY 2012(from January 1, 2012
to December 31, 2012)Retirement benefit expenses

2,133

2,091

311

224

1,822

1,867

(1) Service costs(2) Contribution made for defined contribution pension plan

4. Assumption used in accounting for retirement benefit obligation
Actuarial assumption is omitted since the Company applies the simplified method.

- 35 -FY 2013(from January 1, 2013
to December 31, 2013)

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

(Stock options)
1. The account name and the amount of stock options charged as expenses(Unit: thousands of yen)

Selling, general andadministrative expenses

FY 2012(from January 1, 2012
to December 31, 2012)

FY 2013(from January 1, 2013
to December 31, 2013)27,16766,534

2. Description of stock options/ Changes in the size of stock options(1) Description of stock options

Individuals covered by theplan and number of persons
grantedClass and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

The 1st Series
Directors of the Company
3
Auditor & supervisory board member of
the Company
1
Employees of the Company
6
External collaborators
12
Total
22

The 2nd Series

External collaborator

1

Common stock 390,000 shares

Common stock 2,000 shares

June 20, 2005
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires dueto the expiry of her/his term or thecompulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period is not fixed.
From June 21, 2007 to June 20, 2015

June 22, 2005

- 36 -

Same as on the left

Same as on the left
From June 23, 2007 to June 22, 2015

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

The 5th Series
Directors of the Company
1
Individuals covered by the
Employees of the Company 16plan and number of persons
External collaborators
1
grantedTotal
18
Class and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

Individuals covered by theplan and number of persons
grantedClass and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

Common stock

117,000 shares

January 31, 2006
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires dueto the expiry of her/his term or thecompulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period is not fixed.
From February 1, 2008 to September 1,
2015
The 7th Series
Directors of the Company
6
Auditors & supervisory board membersof the Company
2
Employees of the Company
16
External collaborators
9
Total
33
Common stock

200,000 shares

July 1, 2006
1. The persons granted must be in astatus of the Company’s director,
auditor & supervisory board
member, advisor or employee atthe time of exercise. However, thisis not necessarily the case if theperson granted retires due to the
expiry of her/his term or thecompulsory retirement, if
otherwise the board of directors
approves, or if the person granted
is an external collaborator.
2. The Company’s stock must be listed
on a stock exchange.
Vesting period is not fixed.
From July 2, 2008 to March 30, 2016

- 37 -The 6th Series
Auditors & supervisory board members of
the Company
1
Employees of the Company
3
External collaborators
6
Total
10
Common stock

45,000 shares

April 18, 2006

Same as on the left

Same as on the left
From April 19, 2008 to March 30, 2016

The 8th Series
Employees of the Company
External collaborators
Total

Common stock

6
5
11

52,000 shares

December 4, 2006

Same as on the left

Same as on the left
From December 2, 2008 to March 30, 2016

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

The 9th Series
The 11th Series
Directors of the Company
3
Individuals covered by the
Employees of the Company
6
Auditors & supervisory board members ofplan and number of persons
External collaborators
3
the Company
2
granted
Total
9
Total
5
Class and number of shares
Common stock 66,000 shares
Common stock 34,000 shares
to be issued upon theexercise of the stock option
Grant dateFebruary 1, 2007
March 15, 2007
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires due
Vesting condition
Same as on the left
to the expiry of her/his term or thecompulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period
Vesting period is not fixed.
Same as on the left
From January 24, 2009 to January 23,
From March 3, 2009 to March 2, 2017
Exercise period
2017

Individuals covered by theplan and number of persons
grantedClass and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

The 12th Series
Directors of the Company
5
Auditor & supervisory board memberof the Company
1
Total
6
Common stock

82,000 shares

The 13th Series
Employees of the Company
External collaborators
Total
Common stock

33
12
45

170,000 shares

August 29, 2007
August 29, 2007
1. The persons granted must be in astatus of the Company’s director,
auditor & supervisory board
member, advisor or employee atthe time of exercise. However, thisis not necessarily the case if theperson granted retires due to theSame as on the left
expiry of her/his term or thecompulsory retirement, if otherwise
the board of directors approves, orif the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period is not fixed.
Same as on the left
From August 29, 2009 to August 28, 2017 From August 29, 2009 to August 28, 2017

- 38 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

The 14th Series
The 16th Series
Directors of the Company
5
Individuals covered by the
Auditor & supervisory board member ofplan and number of persons
External collaborators
14
the Company
1
grantedTotal
6
Class and number of shares
Common stock 207,000 shares
Common stock 85,000 shares
to be issued upon theexercise of the stock option
Grant date
October 1, 2008
October 1, 2008
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires due
Vesting condition
Same as on the left
to the expiry of her/his term or thecompulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period
Vesting period is not fixed.
Same as on the left
From October 1, 2010 to September 30,
From October 1, 2010 to September 30,
Exercise period
2018
2018

Individuals covered by theplan and number of persons
grantedClass and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

The 17th Series
Directors of the Company
3
Auditor & supervisory board member of
the Company
1
Total
4
Common stock

72,000 shares

March 18, 2009
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires dueto the expiry of her/his term or thecompulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period is not fixed.
From March 19, 2011 to March 18, 2019- 39 -

The 19th Series
External collaborators

Common stock2

12,500 shares

March 18, 2009Same as on the left

Same as on the left
From March 19, 2011 to March 18, 2019

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

Individuals covered by theplan and number of persons
grantedClass and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

The 20th Series
Directors of the Company
6
Auditor & supervisory board member of
the Company
1
Total
7
Common stock

361,000 shares

March 31, 2010
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires dueto the expiry of her/his term or thecompulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period is not fixed.
From April 1, 2012 to March 31, 2020

(This part is intentionally left blank)- 40 -The 21st Series
Employees of the Company

Common stock50

326,500 shares

March 31, 2010Same as on the left

Same as on the left
From April 1, 2012 to March 31, 2020

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

The 22nd Series
Individuals covered by theplan and number of persons
grantedClass and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

External collaborators

Common stock

The 23rd Series
13

Employees of the Company

153,000 shares

Common stock

March 31, 2010
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires dueto the expiry of her/his term or thecompulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period is not fixed.
From April 1, 2012 to March 31, 2020

The 24th Series
Individuals covered by theplan and number of persons
grantedClass and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

Directors of the Company

Common stock

32,000 shares

October 15, 2010Same as on the left

Same as on the left
From October 15, 2012 to October 14,
2020
The 25th Series

5

192,000 shares

March 31, 2011
1. The persons granted must be in a statusof the Company’s director, auditor &supervisory board member, advisor or
employee at the time of exercise.
However, this is not necessarily thecase if the person granted retires dueto the expiry of her/his term or thecompulsory retirement, if otherwise
the board of directors approves, or if
the person granted is an external
collaborator.
2. The Company’s stock must be listed ona stock exchange.
Vesting period is not fixed.
From March 31, 2013 to March 30, 2021

- 41 -

9

Employees of the Company

Common stock59

195,000 shares

March 31, 2011

Same as on the left

Same as on the left
From March 31, 2013 to March 30, 2021

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

The 26th Series
Individuals covered by theplan and number of persons
grantedClass and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

Directors of the Company

Common stock

The 27th Series
4

Employees of the Company

362,500 shares

Common stock

May 2, 2012
No specific conditions are prescribed in
the allotment agreement of stockacquisition rights entered between the
Company and the person granted, except
for certain vesting conditions stipulated in
the exercise condition. The exercise
conditions are described in *(1) to (6).
The period that fulfills the requirement of
the exercise condition* (2) and (3).
From April 18, 2014 to April 17, 2022
The 28th Series

Individuals covered by theplan and number of persons
grantedClass and number of shares
to be issued upon theexercise of the stock option
Grant date

Vesting condition

Vesting period
Exercise period

Employees of the Company

Common stock

5

16,500 shares

Vesting condition

Vesting period
Exercise period

Common stock

68

124,000 shares

May 29, 2013
No specific conditions are prescribed in
the allotment agreement of stockacquisition rights entered between the
Company and the person granted, except
for certain vesting conditions stipulated in
the exercise condition. The exercise
conditions are described in *(1) to (6).
The period that fulfills the requirement of
the exercise condition *(2) and (3).
From May 15, 2015 to May 14, 2023
- 42 -

May 2, 2012Same as on the left

Same as on the left
From April 18, 2014 to April 17, 2022

Directors of the Company

Common stock

September 28, 2012
No specific conditions are prescribed in
the allotment agreement of stockacquisition rights entered between the
Company and the person granted, except
for certain vesting conditions stipulated in
the exercise condition. The exercise
conditions are described in *(1) to (6).
The period that fulfills the requirement of
the exercise condition *(2) and (3).
From September 14, 2014 to September
13, 2022

Employees of the Company

430,700 shares

The 30th Series

The 31st Series
Individuals covered by theplan and number of persons
grantedClass and number of shares
to be issued upon theexercise of the stock option
Grant date70

5116,000 shares

May 29, 2013Same as on the left

Same as on the left
From May 15, 2015 to May 14, 2023

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013*(1) Fraction less than one unit of a stock acquisition right shall be un-exercisable.
(2) Those who were granted the right may exercise all or part of the rights in accordance with the following classifications:＜The 26th Series and the 27th Series stock option＞(a) Those who were granted the stock acquisition rights may exercise the rights within the limit of one-fourth (1/4) from
April 18, 2014 to April 17, 2015.
(b) Those who were granted the stock acquisition rights may exercise the rights within the limit of one-half (1/2) from April
18, 2015 to April 17, 2016.
(c) Those who were granted the stock acquisition rights may exercise the rights within the limit of three-fourths (3/4) from
April 18, 2016 to April 17, 2017(d) Those who were granted the stock acquisition rights may exercise all the rights from April 18, 2017 to April 17, 2022
＜The 28th Series stock option＞(a) Those who were granted the stock acquisition rights may exercise the rights within the limit of one-fourth (1/4) from
September 14, 2014 to September 13, 2015.
(b) Those who were granted the stock acquisition rights may exercise the rights within the limit of one-half (1/2) from
September 14, 2015 to September 13, 2016.
(c) Those who were granted the stock acquisition rights may exercise the rights within the limit of three-fourths (3/4) from
September 14, 2016 to September 13, 2017.
(d)Those who were granted the stock acquisition rights may exercise all the rights from September 14, 2017 to September
13, 2022.

＜The 30th and the 31st Series stock option＞(e) Those who were granted the stock acquisition rights may exercise the rights within the limit of one-fourth (1/4) from May
15, 2015 to May 14, 2016.
(f)

Those who were granted the stock acquisition rights may exercise the rights within the limit of one-half (1/2) from May
15, 2016 to May 14, 2017.

(g) Those who were granted the stock acquisition rights may exercise the rights within the limit of three-fourths (3/4) fromMay 15, 2017 to May 14, 2018.
(h)Those who were granted the stock acquisition rights may exercise all the rights from May 15, 2018 to May 14, 2023.

(3) Those who received the allotment of the stock acquisition rights (hereinafter the "“Person Granted”) must be in a status of thedirector, auditor & supervisory board member or employee of the Company or its affiliates at the time of exercise. However,this is not necessarily the cases where;(a) The Person Granted is the director or auditor & supervisory board member of the Company or its affiliates and retires dueto the expiry of her/his term.
(b) The Person Granted is the employee of the Company or its affiliates and retires due to the compulsory retirement.
(c) The Person Granted is the director, auditor & supervisory board member or employee of the Company or its affiliates andthe board of directors resolves that he/she resigns or retires with honorable recognition.
(4) The Person Granted shall exercise the rights starting from the date of resolution by the below-mentioned stockholders’ meetingor the board of directors’ meeting until one day before the effective date of the Organizational Restructuring as followed,
regardless the conditions of exercise period originally stipulated, when the Organizational Restructuring are approved by the
resolution of the Company’s stockholders’ meeting (including the case where resolution of a stockholders’ meeting is deemed
to exist pursuant to the provision of Article 319 of the Companies Act) or the board of directors’ meeting (limited to the casewhere no stockholders’ meeting is required for the said Organizational Restructuring) before the exercise period (hereinafter“Exercise Period”) of the stock acquisition rights comes into effect: an absorption-type merger or an incorporation-typemerger where the Company becomes a dissolving company and an absorption-type split or an incorporation-type company
split where the Company becomes a split company or a share exchange or a share transfer where the Company becomes awholly-owned subsidiary (collectively, “Organizational Restructuring” as mentioned above).

- 43 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013(5) In the event where;(a) The Person Granted died before the exercise period comes into effect, the inheritor shall exercise the rights of up to one-half(1/2) within six months from the date of inherited, or(b) The Person Granted died during the exercise period, the inheritor shall exercise all the rights within six months from thedate of inherited.
However, in the event that the inheritor died, the rights shall be discarded and shall not be exercised by his/her inheritor.
(6) The stock acquisition rights shall not be offered for pledge or disposed of in any other way.

(This part is intentionally left blank)- 44 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

(2) Change in the size of stock option
The number of stock option is converted into the number of shares subject to the numbers exist in FY2013.
(a) Number of stock options(Unit: number of shares)stndth
The 1 Series
The 2 Series
The 5 Series
The 6th Series
Grant dateJune 20, 2005
June 22, 2005
January 31, 2006
April 18, 2006
Non-vested shares:
At the beginning of the year－－－－
Granted－－－－Expired－－－－
Vested－－－－At the end of the year－－－－
Vested shares:
At the beginning of the year
351,000
2,000
2,000
2,000
Vested－－－－Exercised
59,0002,000－－
Expired－－－－At the end of the year
292,000
－
2,000
2,000

th

Grant dateNon-vested shares:
At the beginning of the year
GrantedExpired
VestedAt the end of the year
Vested shares:
At the beginning of the year
VestedExercised
ExpiredAt the end of the year

Grant dateNon-vested shares:
At the beginning of the year
GrantedExpired
VestedAt the end of the year
Vested shares:
At the beginning of the year
VestedExercised
ExpiredAt the end of the yearth

The 7 Series
July 1, 2006

The 8 Series
December 4, 2006

(Unit: number of shares)
The 9 Series
The 11th Series
February 1, 2007
March 15, 2007
th

－
－
－
－
－

－
－
－
－
－

－
－
－
－
－

－
－
－
－
－

61,000－－－61,000

1,000
－
－
－
1,000

3,000
－
－
－
3,000

7,000
－
－
－
7,000

The 12th Series
August 29, 2007

The 13th Series
August 29, 2007

－
－
－
－
－

－
－
－
－
－

－
－
－
－
－

－
－
－
－
－

23,000－－－23,00061,000－－－61,00028,000－－－28,00070,000－－－70,000- 45 -(Unit: number of shares)
The 14th Series
The 16th Series
October 1, 2008
October 1, 2008

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013thGrant dateNon-vested shares:
At the beginning of the year
GrantedExpired
VestedAt the end of the year
Vested shares:
At the beginning of the year
VestedExercised
ExpiredAt the end of the year

(Unit: number of shares)
The 20 Series
The 21st Series
March 31, 2010
March 31, 2010th

The 17 Series
March 18, 2009

The 19 Series
March 18, 2009

－
－
－
－
－

－
－
－
－
－

－
－
－
－
－

－
－
－
－
－

4,000
－
－
－
4,000

2,500
－
－
－
2,500

361,000－
16,500－344,500

259,500－
2,000
23,000234,500nd

Grant dateNon-vested shares:
At the beginning of the year
GrantedExpired
VestedAt the end of the year
Vested shares:
At the beginning of the year
VestedExercised
ExpiredAt the end of the yearthrd

(Unit: number of shares)
The 24 Series
The 25th Series
March 31, 2011
March 31, 2011th

The 22 Series
March 31, 2010

The 23 Series
October 15, 2010

－
－
－
－
－

－
－
－
－
－

192,000－－
192,000－

185,000－
5,000
180,000－

153,000－－－
153,000

32,000－－6,000
26,000－
192,000－－
192,000－
180,000－
16,500163,500- 46 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

Grant dateNon-vested shares:
At the beginning of the year
GrantedExpired
VestedAt the end of the year
Vested shares:
At the beginning of the year
VestedExercised
ExpiredAt the end of the year

Grant dateNon-vested shares:
At the beginning of the year
GrantedExpired
VestedAt the end of the year
Vested shares:
At the beginning of the year
VestedExercised
ExpiredAt the end of the year

The 26th Series
May 2, 2012

The 27th Series
May 2, 2012

(Unit: number of shares)
The 28th Series
The 30th Series
September 28, 2012
May 29, 2013

362,500－－－
362,500

401,400－
33,100－368,300

16,500－500－
16,000－116,000－－
116,000

－
－
－
－
－

－
－
－
－
－

－
－
－
－
－

－
－
－
－
－

(Unit: number of shares)
The 31st Series
May 29, 2013－
124,000
8,400－
115,600－－－－－- 47 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013(b) Per share prices
Grant date
Exercise price (yen) (Note 1)
Average stock price at thetime of exercise (yen)Fair value price at grant date(yen)

Grant date
Exercise price (yen) (Note 1)
Average stock price at thetime of exercise (yen)Fair value price at grant date(yen)

Grant date
Exercise price (yen) (Note 1)
Average stock price at thetime of exercise (yen)Fair value price at grant date(yen)

Grant date
Exercise price (yen) (Note 1)
Average stock price at thetime of exercise (yen)Fair value price at grant date(yen)

Grant date
Exercise price (yen) (Note 1)
Average stock price at thetime of exercise (yen)Fair value price at grant date(yen)

Grant date
Exercise price (yen) (Note 1)
Average stock price at thetime of exercise (yen)Fair value price at grant date(yen)

The 1st Series
June 20, 2005
487

The 2nd Series
June 22, 2005
500

The 5th Series
January 31, 2006
974

The 6th Series
April 18, 2006
974

880

711

－

－

－

－

－

－

The 7th Series
July 1, 2006
1,461

The 8th Series
December 4, 2006
1,461

The 9th Series
February 1, 2007
1,461

The 11th Series
March 15, 2007
1,461

－

－

－

－

0

0

0

0

The 12th Series
August 29, 2007
1,461

The 13th Series
August 29, 2007
1,461

The 14th Series
October 1, 2008
1,169

The 16th Series
October 1, 2008
1,169

－

－

－

－

0

0

0

0

The 17th Series
March 18, 2009
1,169

The 19th Series
March 18, 2009
1,169

The 20th Series
March 31, 2010
585

The 21st Series
March 31, 2010
585

－

－

1,034

880

0

0

0

0

The 22nd Series
March 31, 2010
585

The 23rd Series
October 15, 2010
585

The 24th Series
March 31, 2011
682

The 25th Series
March 31, 2011
682

－

－

－

－

0

0

0

0

The 26th Series
May 2, 2012
555

The 27th Series
May 2, 2012
555

The 28th Series
September 28, 2012
555

The 30th Series
May 29, 2013
799

－

－

－

－

(a) 179(a) 179(a) 203(a) 586(b) 187(c) 195(b) 187(c) 195(b) 208(c) 213(b) 602(c) 617(d) 202(d) 202(d) 217(d) 631- 48 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

Grant date
Exercise price (yen) (Note 1)
Average stock price at thetime of exercise (yen)Fair value price at grant date(yen)

The 31st Series
May 29, 2013799－(a) 586(b) 602(c) 617(d) 631

Note: 1. The Company increased its capital through the public offering on December 4, 2013 and through the third party
allotment on December 25, 2013, at the per share amount less than the exercise price of options. Thus, theexercise amounts above are stated after price adjustments clause.
2. Each of (a), (b), (c) and (d) above is corresponding to (a), (b), (c) and (d) of exercise period in the table shownon 2 (1).
3. Method for estimating the fair value of stock options
The method for estimating the fair value of stock options that were granted during this fiscal year is estimated basedon the following method.
(1) Estimate technique used: Black-Scholes option pricing model(2) Major assumptions and estimate method
The 30th Series
The 31st Series
Volatility of stock price (Note 2)
86.59%
86.59%
Estimated remaining outstanding(a) 5.96 years(a) 5.96 years
period (Note 3)(b) 6.46 years(b) 6.46 years

Estimated dividend (Note 4)
Risk free interest rate (Note 5)(c) 6.96 years(c) 6.96 years(d) 7.46 years(d) 7.46 years

0 yen per share

0 yen per share(a) 0.402％(a) 0.402％(b) 0.520％(c) 0.634％(b) 0.520％(c) 0.634％(d) 0.797％(d) 0.797％

Note: 1. Each of (a), (b), (c) and (d) above is corresponding to (a), (b), (c) and (d) of exercise period in the table shown on 2 (1).
2. The calculation was made based on the historical stock quotes by each classification below.
The calculation was made based on the historical stock quotes during the period from June 6, 2011 to May 29, 2013.
Since the Company listed on the stock exchange on October 20, 2011, stock quotes were not available during the period
from June 6, 2011 to October 19, 2011. The Company selected several companies which were very close in resemblance to
the Company and used their historical quotes for the period.
3. Since it is very difficult to make reliable estimates due to insufficient historical data, the remaining period was calculated
based on the assumption that the rights were exercised in the middle of each exercise period.
4. The Company estimates dividends to be zero since no dividends have been paid in the past.
5. It represents yields of Japanese government bonds corresponding to estimated remaining outstanding period.

4. Estimation of the number of stock options vested
The number of expired shares is estimated based on the historical turnover ratio.

- 49 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

(Deferred tax accounting)
1. Significant components of deferred tax assets and liabilities(Unit: thousands of yen)
FY 2012(as of December 31, 2012)
Deferred tax assets:
Excess depreciation for lump-sum depreciable
assetsExcess depreciation for depreciable assets
Excess amortization for deferred assets
Research and development expenses
Accounts payables-trade
Account payable-other
Provision for retirement benefits
Enterprise tax payable
Asset retirement obligation
Share-based compensation expense
Loss carried forward
Subtotal
Valuation allowance
Total deferred tax assets
Deferred tax liabilities
Valuation difference on available-for-salesecurities
Total deferred tax liabilities
Net deferred tax assets

FY2013(as of December 31, 2013)

1,094

1,920

621
212,730
836,309
14,89919,905
601
5,203
3,143
4,908
1,454,943
2,554,361(2,554,361)－

501
145,726
607,327－
14,536
596
7,850
3,736
16,8292,012,894
2,811,921(2,811,921)
－

－

102

－
－

102
－

2. The reconciliation between the effective tax rates reflected in the financial statements and the statutory tax rate isomitted since the Company reported loss before income taxes for the years ended December 31, 2012 and 2013.

(Equity in earnings)
None to be reported.

(Asset retirement obligations)
The Company has future restoration obligations related to leasehold contracts of office premises.
Carrying the balance of lease and guarantee deposits as an asset, the Company reasonably estimates non-recoverable
amounts of lease and guarantee deposits under lease contracts and records the amount attributable to the respective
fiscal year as expenses, instead of accounting for asset retirement obligations by recognizing a liability and an
associated asset.

(Investment and rental property)
None to be reported.

- 50 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

(Segment information)【Segment information】
FY 2012 (from January 1, 2012 to December 31, 2012) and FY 2013 (from January 1, 2013 to December 31, 2013)
Segment information is omitted since the Company operates a single segment of pharmaceutical businesses
including research and development of pharmaceutical drugs as well as manufacturing and marketing and otherrelated activities.

【Related information】
FY 2012 (from January 1, 2012 to December 31, 2012)
1. Information by product and service
Information by product and service is omitted since external sales of a single service category account for morethan 90% of total net sales stated in the statement of income.
2. Information about geographical area
(1) Net sales
Net sales information about geographical area is omitted since external sales to Japanese customers account for
more than 90% of total net sales stated in the statement of income.
(2) Property, plant and equipment
All property, plant and equipment are located in Japan.
3. Information by major customer(Unit: thousands of yen)
Name of customer
Eisai Co., Ltd.

Net sales

Name of related segment

1,929,615

Pharmaceutical businesses including research and developmentof pharmaceutical drugs as well as manufacturing marketingand other related activities.

FY 2013 (from January 1, 2013 to December 31, 2013)
1. Information by product and service
Information by product and service is omitted since external sales of a single service category account for morethan 90% of total net sales stated in the statement of income.
2. Information about geographical area
(1) Net sales
Net sales information about geographical area is omitted since external sales to Japanese customers account for
more than 90% of total net sales stated in the statement of income.
(2) Property, plant and equipment
All property, plant and equipment are located in Japan.
3. Information by major customer(Unit: thousands of yen)
Name of customer
Eisai Co., Ltd.

Net sales

Name of related segment

1,485,877

Pharmaceutical businesses including research and developmentof pharmaceutical drugs as well as manufacturing marketingand other related activities.

【Information about impairment loss on long-lived assets by reportable segment】
FY 2012 (from January 1, 2012 to December 31, 2012) and FY 2013 (from January 1, 2013 to December 31, 2013)
None to be reported.
- 51 -

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

【Information about the amortization and unamortized balance of goodwill by reportable segment】
FY 2012 (from January 1, 2012 to December 31, 2012) and FY 2013 (from January 1, 2013 to December 31, 2013)
None to be reported.
【Information about the gain recognized on negative goodwill by reportable segment】
FY 2012 (from January 1, 2012 to December 31, 2012) and FY 2013 (from January 1, 2013 to December 31, 2013)
None to be reported.

(Related parties information)
None to be reported.

(Per share information)
FY 2012(from January 1, 2012
to December 31, 2012)

FY 2013(from January 1, 2013
to December 31, 2013)

Net assets per share

254.71 yen

Net assets per share

239.48 yen

Net loss per share(90.60) yen

Net loss per share(69.29) yen

While having potential dilutive stocks, diluted net income
per share is not provided since the Company reported net
loss per share.

While having potential dilutive stocks, diluted net income
per share is not provided since the Company reported net
loss per share.

(Note 1) The basis for calculating net loss per share is as follows:
FY 2012(from January 1, 2012
to December 31, 2012)
Net loss (thousand yen)
(1,733,320)
Amount not attributable to the shareholders of－common stock (thousand yen)
Net loss attributable to the shareholders of common(1,733,320)
stock (thousand yen)
Average number of shares outstanding during the19,130,825
year (shares)
Description of potential dilutive stocks not included 23 types of Stock acquisitionrights (25,804 units) inin the earning-per-share calculation due to antiaccordance with thedilutive.
Commercial Code of 1890
Article 280 (20) and (21), andCompanies Act Article 236,
238, and 239.

- 52 -FY 2013(from January 1, 2013
to December 31, 2013)(1,605,224)－(1,605,224)
23,167,804
23 types of Stock acquisitionrights (23,564 units) inaccordance with theCommercial Code of 1890
Article 280 (20) and (21), andCompanies Act Article 236,
238, and 239.

SymBio Pharmaceuticals Limited (4582) Summary of Financial Statements [Japanese GAAP] (Non-consolidated)
Results for the fiscal year ended December 31, 2013

(Note 2) The basis for calculating net assets per share is as follows:
FY 2012(from January 1, 2012
to December 31, 2012)
Net assets (thousand yen)Amount to be deducted from net assets(Of which, Stock acquisition right herein)
Net assets attributable to the shareholders ofcommon stock (thousand yen)
Number of shares used in the calculation of net
assets per share (shares)(Significant subsequent events)
None to be reported.
5. Other(1) Changes in Officers
None to be reported.
(2) Other
None to be reported.

- 53 -FY 2013(from January 1, 2013
to December 31, 2013)

4,899,957
27,167(27,167)

7,432,996
96,761(96,761)

4,872,790

7,336,234

19,130,825

30,634,182